

## Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Anti-Tumor Activity

Paul Robert Leger, Dennis X Hu, Berenger Biannic, Minna Bui, Xiping Han, Emily Karbarz, Jack Maung, Akinori Okano, Maksim Osipov, Grant M. Shibuya, Kyle Young, Christopher Higgs, Betty Abraham, Delia Bradford, Cynthia Cho, Christophe Colas, Scott Jacobson, Yamini M. Ohol, Deepa Pookot, Payal Rana, Jerick Sanchez, Niket Shah, Michael Sun, Steve Wong, Dirk G. Brockstedt, Paul D. Kassner, Jacob B. Schwarz, and David J. Wustrow

*J. Med. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.0c00245 • Publication Date (Web): 17 Apr 2020

Downloaded from [pubs.acs.org](https://pubs.acs.org) on April 17, 2020

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

# Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Anti-Tumor Activity

*Paul R. Leger<sup>††</sup>, Dennis X. Hu<sup>††</sup>, Berenger Biannic<sup>‡</sup>, Minna Bu<sup>‡</sup>, Xinpeng Han<sup>‡</sup>, Emily Karbarz<sup>‡</sup>, Jack Maung<sup>‡</sup>, Akinori Okano<sup>‡</sup>, Maksim Osipov<sup>‡</sup>, Grant M. Shibuya<sup>‡</sup>, Kyle Young<sup>‡</sup>, Christopher Higgs<sup>§</sup>, Betty Abraham<sup>‡</sup>, Delia Bradford<sup>‡</sup>, Cynthia Cho<sup>‡</sup>, Christophe Colas<sup>‡</sup>, Scott Jacobson<sup>‡</sup>, Yamini M. Oho<sup>‡</sup>, Deepa Pooko<sup>‡</sup>, Payal Rana<sup>‡</sup>, Jerick Sanchez<sup>‡</sup>, Niket Shah<sup>‡</sup>, Michael Sun<sup>‡</sup>, Steve Wong<sup>‡</sup>, Dirk G. Brockstedt<sup>‡</sup>, Paul D. Kassner<sup>‡</sup>, Jacob B. Schwarz<sup>‡</sup>, David J. Wustrow<sup>\*‡</sup>*

<sup>††</sup>RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, CA 94080

<sup>§</sup>Schrödinger, 120 West 45<sup>th</sup> Street, New York, NY 10036

**ABSTRACT.** USP7 is a promising target for cancer therapy as its inhibition is expected to decrease function of oncogenes, increase tumor suppressor function, and enhance

1  
2  
3 immune function. Using a structure-based drug design strategy, a new class of  
4  
5  
6  
7 reversible USP7 inhibitors has been identified that is highly potent in biochemical and  
8  
9  
10 cellular assays and extremely selective for USP7 over other deubiquitinases (DUBs).  
11  
12  
13  
14 The succinimide was identified as a key potency-driving motif, forming two strong  
15  
16  
17 hydrogen-bonds to the allosteric pocket of USP7. Re-design of an initial benzofuran-  
18  
19  
20 amide scaffold yielded a simplified ether series of inhibitors, utilizing acyclic  
21  
22  
23 conformational control to achieve proper amine placement. Further improvements were  
24  
25  
26  
27 realized upon replacing the ether-linked amines with carbon-linked morpholines, a  
28  
29  
30 modification motivated by Free Energy Perturbation (FEP+) calculations. This led to the  
31  
32  
33  
34 discovery of compound **41**, a highly potent, selective, and orally bioavailable USP7  
35  
36  
37  
38 inhibitor. In xenograft studies, compound **41** demonstrated tumor growth inhibition in  
39  
40  
41 both p53 wildtype and p53 mutant cancer cell lines, demonstrating that USP7 inhibitors  
42  
43  
44  
45 can suppress tumor growth through multiple different pathways.  
46  
47  
48  
49

## 50 INTRODUCTION


51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Ubiquitin-specific protease 7 (USP7), also known as HAUSP, is an enzyme  
5  
6  
7 which cleaves ubiquitin groups from specific ubiquitinated client proteins.<sup>1</sup> This de-  
8  
9  
10 ubiquitination activity can rescue the client proteins from proteasome-mediated  
11  
12  
13 degradation and result in a net increase in concentration of these proteins. Through this  
14  
15  
16 mechanism, USP7 is proposed to stabilize the oncogenic E3 ubiquitin ligase MDM2, a  
17  
18  
19 negative regulator of the tumor suppressor p53.<sup>2</sup> USP7 has also been reported to play a  
20  
21  
22 role in stabilizing FOXP3, an essential transcription factor for the development and  
23  
24  
25 function of regulatory T cells, and hence may play a role in the suppression of immune  
26  
27  
28 responses to tumors.<sup>3</sup> Additionally, USP7 may stabilize several proteins involved in  
29  
30  
31 DNA damage repair.<sup>4</sup> Pharmacological inhibition of USP7 may therefore be beneficial  
32  
33  
34 for cancer therapy through multiple mechanisms.  
35  
36  
37  
38  
39  
40  
41

42 A number of USP7-selective reversible inhibitors have recently been reported.<sup>5</sup>  
43  
44  
45 These include 4-hydroxy piperidine inhibitors **1-4** (Figure 1) disclosed by Hybrigenics,<sup>6</sup>  
46  
47  
48 FORMA Therapeutics,<sup>7</sup> Almac Discovery,<sup>8</sup> Servier,<sup>9</sup> and others,<sup>10</sup> as well as tri-aryl  
49  
50  
51 inhibitors such as **5** disclosed by Genentech.<sup>11,12</sup> 4-hydroxy piperidine inhibitors such as  
52  
53  
54  
55 **2-4** have been reported to bind to an allosteric pocket in the “palm” domain of USP7  
56  
57  
58  
59  
60

(Figure 2). Small molecule binding to this allosteric site is believed to stabilize an inactive conformation of USP7, preventing USP7 catalytic activity.<sup>7</sup> The tri-aryl inhibitors such as **5** are reported to bind in a different allosteric pocket in the “palm” domain of USP7.

USP7.



**Figure 1.** Examples of previously described USP7 inhibitors.

Many studies interrogating the biological functions of USP7 have employed irreversible active-site dual inhibitors of USP7 and USP47, such as P22077 (**6**, Figure 1).<sup>13,14</sup> Potent, DUB-selective, and reversible inhibitors of USP7 of diverse chemotypes would be useful tools in clarifying and assessing the many potential biological roles of


1  
2  
3  
4 USP7 and its relevance as a target for human cancer therapy. Here we report an  
5  
6  
7 optimization campaign resulting in a new class of highly potent, selective, reversible,  
8  
9  
10 and bioavailable inhibitors of USP7. These inhibitors have recently aided the  
11  
12  
13 clarification of the biological activities of USP7.<sup>15</sup>  
14  
15  
16  
17  
18  
19  
20

## 21 RESULTS AND DISCUSSION

### 22 *23 Pyridylbenzofurans as Starting Chemical Matter*


24  
25  
26  
27  
28 Our drug discovery campaign for USP7 inhibitors began with an evaluation of  
29  
30  
31 compounds derived from a focused library screen of known DUB inhibitors as well as  
32  
33  
34 other structurally related compounds. Anticipating DUB-selectivity to be a major  
35  
36  
37 challenge for a USP7 program based on the conserved nature of DUB active sites, early  
38  
39  
40 chemical matter was tested for biochemical activity against USP7 as well as against  
41  
42  
43 USP1, UCH-L3, and USP47. Among the USP7-active compounds evaluated, the 7-  
44  
45  
46 pyridylbenzofuran compound **7** (Figure 2) stood out as an attractive starting point for  
47  
48  
49 optimization due to its relatively high selectivity for USP7 over related de-ubiquitinating  
50  
51  
52  
53 enzymes. Interestingly, co-crystallizations of 4-hydroxy piperidine compound **1** and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 benzofuran **7** with USP7 revealed that both inhibitors occupy the same allosteric pocket  
4  
5  
6  
7 of the palm region, even though they belong to different chemotypes (Figure 2).  
8  
9



**Figure 2.** (Left) Schematic of the catalytic domain of USP7 (orange) bound to ubiquitin (blue), with the palm region (below purple dashed line), tunnel area (red box), and catalytic site (green circle) highlighted. The yellow arrow indicates the compound binding region highlighted in the structures on the right. (Right) Comparison of co-crystal structures of 4-hydroxy piperidine inhibitor **1** and pyridylbenzofuran compound **7**. Both inhibitors bind to the same allosteric site of USP7 and are selective inhibitors of USP7. The PDB code for **1** bound to USP7 is 6VN4. The PDB code for **7** bound to USP7 is 6VN5.


1  
2  
3  
4 Benzofuran compound **7** and 4-hydroxy piperidine compound **1** form many  
5  
6  
7 similar interactions with the USP7 protein despite their distinct structures. Both  
8  
9  
10 compounds form hydrogen-bonds with the backbone nitrogen of Val-296, the phenol  
11  
12  
13 moiety of Tyr-465, and the carboxylate of Asp-295. Importantly, despite the two  
14  
15  
16 compounds similar potencies, there appeared to be interactions made by compound **1**  
17  
18  
19 with USP7 that were not made by compound **7** (Figure 3), suggesting that it should be  
20  
21  
22 possible to enhance compound **7**'s affinity towards USP7 by introducing novel elements  
23  
24  
25 that would take advantage of additional interactions in the binding pocket. It was  
26  
27  
28 hypothesized that the potency of a compound such as benzofuran **7** could be improved  
29  
30  
31 by introducing functionality which could target the backbone hydrogen bond donor of  
32  
33  
34 Phe-409 with an appropriately linked hydrogen-bond acceptor, or which could better  
35  
36  
37 engage the glutamine side chain of Gln-297.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 3.** Comparison of USP7 binding interactions of 4-hydroxy piperidine inhibitor **1** and pyridylbenzofuran inhibitor **7**. Boxed residues indicate potential hydrogen-bonding interactions that are not utilized by compound **7**. The PDB code for **1** bound to USP7 is 6VN4. The PDB code for **7** bound to USP7 is 6VN5.

WaterMap<sup>16</sup> analysis of the holo structure (ligand removed) revealed several unfavorable hydration sites in the binding site of **7** (Figure 4). Unfavorable hydration sites can be characterized as sites that have a predicted free energy  $\Delta G$  of  $> 0$  kcal/mol upon adding water while favorable hydration sites have a predicted free energy  $\Delta G$  of  $< 0$  kcal/mol. Binding of compound **7** likely displaces several of the water molecules as

1  
2  
3 shown by the magnified hydration sites of Figure 4A, including a high-energy site filled  
4  
5  
6  
7 by the aryl chloride moiety of **7**. However, sites adjacent to the aminopyridine are not  
8  
9  
10 displaced by the ligand, corroborating the proposed hypothesis that adding appropriate  
11  
12  
13 functionality in this region could lead to improved potency. This was further confirmed  
14  
15  
16  
17 by a WaterMap analysis with compound **7** present in the complex, showing that the  
18  
19  
20 ligand indeed does not displace water sites adjacent to the aminopyridine (Figure 4B).  
21  
22  
23  
24 In fact, the free energy  $\Delta G$  of these sites is even more unfavorable than predicted from  
25  
26  
27  
28 the structure with ligand removed, likely due to a loss of entropy as the waters are  
29  
30  
31 somewhat trapped between the ligand and protein. The combined structural and  
32  
33  
34 computational analysis strongly suggests that efforts to improve the potency of  
35  
36  
37  
38 compound **7** should be focused on changes to the upper pyridine section of the  
39  
40  
41  
42 molecule.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 4.** WaterMap analysis of USP7 binding pocket. Hydration sites are shown as spheres colored by their predicted free energies ( $\Delta G$ ). Green spheres indicate a favorable free energy  $\Delta G$  while red spheres indicate an unfavorable  $\Delta G$ . (A) Hydration sites calculated with the ligand (compound **7**) removed. Overlay of compound **7** indicates that the magnified (enlarged) spheres are predicted to be displaced by compound **7** while the other (smaller) spheres are not. (B) Hydration sites with compound **7** present. Three unfavorable water sites (red/orange) near the 2-aminopyridyl headgroup of **7** suggest opportunities to further improve the potency of this inhibitor. WaterMap analysis based on co-crystal structure of compound **7** and USP7, PDB code 6VN5.

***Addition to the Pyridyl Moiety Improves Potency***

1  
2  
3  
4           Several bicyclic analogs of **7** were first prepared as scaffolds for a potential  
5  
6  
7 hydrogen-bond acceptor (Table 1). Azaindole **8** was isoefficient to 2-aminopyridine **7**,  
8  
9  
10 having increased potency of comparable magnitude to its increased lipophilicity. In  
11  
12  
13 agreement with the selective co-crystallization of the *R*-isomer from racemic 2-  
14  
15  
16 aminopyridine **7** with USP7, asymmetric synthesis of the enantiomers indicated that the  
17  
18  
19 *R*-isomer **9** was significantly more active against USP7, while the *S*-isomer *ent*-**9** was  
20  
21  
22 found to be inactive. Alternative bicyclic scaffolds to the azaindole motif were surveyed.  
23  
24  
25  
26  
27  
28 Thienopyridine **10** was found to be more potent and isoefficient to the corresponding  
29  
30  
31 aza-indole, but with one less hydrogen-bond donor. Substitution of the thienopyridine  
32  
33  
34 with a methyl group (compound **11**) did not lead to a gain in potency, but substitution  
35  
36  
37 with a hydroxymethylene group (compound **12**) did lead to an improvement in potency  
38  
39  
40 while simultaneously reducing lipophilicity. Consistent with the binding mode of these  
41  
42  
43 inhibitors to an allosteric pocket uniquely accessible in USP7, these inhibitors generally  
44  
45  
46 did not display significant activity against USP47 or USP1.<sup>8</sup>  
47  
48  
49  
50  
51  
52

53 **Table 1.** Evaluation of heterocyclic scaffolds<sup>a</sup>  
54  
55  
56  
57  
58  
59  
60



Compound d	R Group	USP7 IC <sub>50</sub> (nM) <sup>b</sup>	USP47 IC <sub>50</sub> (μM) <sup>c</sup>	USP1 IC <sub>50</sub> (μM) <sup>d</sup>	cLogP <sup>e</sup>	LipE <sup>f</sup>
<b>7<sup>g</sup></b>		5600	>80	>80	2.2	2.9
<b>8<sup>g</sup></b>		930	>80	>80	3.1	2.9
<b>9</b>		450	>80	>80	3.1	3.2
<b>10</b>		90	>40	>40	3.9	3.1
<b>11</b>		130	>80	>80	4.4	2.5
<b>12</b>		43	>40	>40	2.9	4.5


<sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.

<sup>c</sup>USP47 biochemical assay. <sup>d</sup>USP1 biochemical assay. <sup>e</sup>Calculated using ChemDraw.

<sup>f</sup>LipE =  $\rho(\text{IC}_{50}) - \text{cLogP}$ . <sup>g</sup>Racemic compound.

1  
2  
3  
4 To further improve potency toward USP7, compounds with an additional  
5  
6  
7 hydrogen bond donor or acceptor near the thienopyridine were explored. It was  
8  
9  
10 expected that additional binding affinity could be achieved in this region by  
11  
12  
13 simultaneously forming interactions with the backbone N–H motifs of either Arg-408 or  
14  
15  
16 Phe-409 and the amide side chain of Gln-297. Interactions with these two residues are  
17  
18  
19 evident in co-crystal structures of USP7 with 4-hydroxy piperidine inhibitor **1** (see Figure  
20  
21  
22  
23  
24 **3**) but are not fully utilized by thienopyridine alcohol **12**. Introduction of an oxetane with  
25  
26  
27 the intention of engaging the side chain of Gln-297 resulted in compound **13** which was  
28  
29  
30 not more potent than compound **12** (Table 2). Serendipitously, the chlorohydrin **14**  
31  
32  
33 resulting from HCl-mediated chlorinolysis of **13** was found to be significantly more active  
34  
35  
36  
37 against USP7 while decreasing overall lipophilicity. Co-crystallization of **14** with USP7  
38  
39  
40 confirmed that this compound was forming the originally desired contacts with Arg-408  
41  
42  
43 and Gln-297 while binding in a reversible manner (Figure 5).  
44  
45  
46  
47  
48


49 **Table 2.** Evaluation of heteroatom-containing headgroups<sup>a</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Compound d	R Group	USP7 IC <sub>50</sub> (nM) <sup>b</sup>	USP47 IC <sub>50</sub> (μM) <sup>c</sup>	cLogP <sup>d</sup>	LipE <sup>e</sup>
12		43	>40	2.9	4.5
13		73	>40	2.8	4.3
14		9	>40	2.6	5.4
15		27	>5	2.3	5.3
16		25	>80	2.7	4.9
17		26	>20	2.8	4.8
18		0.18	>2	2.7	7.0

<sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.


<sup>c</sup>USP47 biochemical assay. <sup>d</sup>Calculated using ChemDraw. <sup>e</sup>LipE =  $\rho(\text{IC}_{50}) - \text{cLogP}$ .



**Figure 5.** Compound **14** co-crystal structure with USP7, highlighting key interactions with the binding pocket. The PDB code for **14** bound to USP7 is 6VN6.

Alternative functional groups to the chloro-diol present in compound **14** were evaluated (Table 2). The pyrimidinone side chain, whose derivatives are present in the hydroxy-piperidine compounds **1-4**, resulted in compound **15** which was found to have slightly better potency than alcohol **12**. Amide or lactam-containing molecules **16** and **17** were not found to have improved potency. However, the addition of a second hydrogen-

1  
2  
3  
4 bond acceptor resulted in succinimide **18**, a compound with sub-nanomolar biochemical  
5  
6  
7 activity against USP7 and excellent lipophilic efficiency. X-ray co-crystallization  
8  
9  
10 confirmed that this succinimidyl functional group was making both interactions with Phe-  
11  
12  
13 409 and Gln-297 (Figure 6). No effect was observed on the potency of USP7 inhibition  
14  
15  
16 with pre-incubation of the succinimide-based inhibitor, indicating that the compound  
17  
18  
19  
20  
21 behaves as a reversible inhibitor as suggested by the crystal structure.<sup>17</sup>  
22  
23  
24  
25  
26




1  
2  
3 **Figure 6.** X-ray co-crystal structure of compound **18** with USP7, highlighting key  
4  
5  
6  
7 interactions with the binding pocket. The PDB code for **18** bound to USP7 is 6VN2.  
8  
9

### 10 11 *A Simplified Ether Series* 12

13  
14  
15 Compound **18** was evaluated in rodent PK and found to have very high clearance  
16  
17  
18 and poor oral exposure, despite reasonable stability in an in vitro hepatocyte stability  
19  
20  
21 assay (Table 3). The low oral exposure was suspected to be in part due to transporter-  
22  
23  
24 mediated efflux resulting from the basic amine moiety of the molecule; however,  
25  
26  
27  
28 compounds without the basic amine motif, which makes multiple key interactions with  
29  
30  
31 Asp-101 and a backbone carbonyl, were orders of magnitude less active against USP7.  
32  
33  
34  
35 Additionally, stability to incubation with hepatocytes was still found to be low for these  
36  
37  
38  
39 compounds. Several isosteric analogs of **18** were prepared where the amide linker was  
40  
41  
42 replaced with a heterocyclic linker in an attempt to improve permeability and stability, a  
43  
44  
45 subset of which are shown in Table 3. Oxazole **19** was found to be less potent than  
46  
47  
48  
49 amide **18** and be less stable to hepatocytes. Isoxazole **20** was found to have good  
50  
51  
52  
53 potency but poor metabolic stability, clearance, and oral exposure. Pyrazole **21** was  
54  
55  
56  
57  
58  
59  
60

found to be more stable to hepatocytes, but unfortunately, this did not extend to a significantly reduced clearance in vivo.

**Table 3.** Evaluation of piperazine-amide replacements



Compound	R Group	USP7 IC <sub>50</sub> (nM) <sup>a,b</sup>	Hepatocyte stability: % remaining (R / H) <sup>c</sup>	IV Clearance (L/hr/kg) <sup>d</sup>	PO AUC (hr*ng/mL) <sup>d</sup>
18		0.18	14% / 37%	11.5	0
19		13	2% / 14%	N.D.	N.D.
20		0.38	4% / 26%	5.8	0
21		1.1	42% / 63%	4.7	0

1  
2  
3  
4 <sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.  
5  
6


7 <sup>c</sup>% remaining after 60-minute incubation with rat (R) or human (H) hepatocytes.  
8  
9

10 <sup>d</sup>Sprague-Dawley rats, dose of 0.5 mg/kg IV, 2 mg/kg PO. N.D. = not determined.  
11  
12  
13

14       Having been unsuccessful at improving PK properties by simple amide  
15 replacement, we were motivated to make more significant modifications to the  
16  
17 dihydrofuran-amide scaffold that had been omnipresent in our inhibitors. Additionally,  
18  
19 these dihydrofuran-containing compounds required relatively lengthy syntheses,  
20  
21 resulting in a slower discovery effort (see Scheme 2). A simplified and metabolically  
22  
23 stable replacement for this bottom portion was desired, but one that maintained the key  
24  
25 contacts with the binding pocket (as highlighted in Figure 6).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38


39       It was believed that a simplified structure such as ether-linked pyrrolidine **22**  
40  
41 might maintain the desired binding interactions while providing better metabolic stability,  
42  
43 a simpler synthesis, and reduced molecular weight (Figure 7). However, this  
44  
45 modification resulted in a 1000-fold potency loss. It became quite clear that while many  
46  
47 aspects of the dihydrofuran-amide did not interact with the binding pocket, it served an  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 important scaffolding role to help place the basic nitrogen in a productive spatial  
4  
5  
6 orientation. Computational modeling indicated that the lowest energy conformation of  
7  
8  
9 dihydrofuran-amide **18** is one in which the piperazine ring is oriented upward, *syn*- to  
10  
11  
12 the pyridine ring system – the same conformation that is adopted upon binding to USP7  
13  
14  
15 (see Figure 6). Conversely, the ground state of simplified system **22** has the basic  
16  
17  
18 nitrogen directed *anti*- to the pyridine ring system. This is a non-productive conformation  
19  
20  
21 and a significant energy penalty is required to achieve proper amine placement in the  
22  
23  
24 binding pocket. To help overcome this unproductive ground state conformation, A-(1,3)  
25  
26  
27 strain was leveraged by installing a methyl group ortho- to the ether linkage (as in  
28  
29  
30 pyrrolidine **23**). This raises the energy of the global minimum conformation of **23** relative  
31  
32  
33 to its bound conformation, increasing the overall free energy of binding with USP7. We  
34  
35  
36  
37  
38  
39  
40  
41 were pleased to see that this simple modification results in a greater than 100-fold  
42  
43  
44 potency gain. A USP7 co-crystal structure of **23** was obtained and showed the  
45  
46  
47  
48 pyrrolidine nitrogen making the same contacts with Asp-295 and Met-292 as the  
49  
50  
51 previous piperazine-amide (Figure 8). Gratifyingly, compound **23** also demonstrated  
52  
53  
54 moderate clearance and non-zero oral bioavailability.  
55  
56  
57  
58  
59  
60



**Figure 7.** A scaffold switch from the benzofuran-amide to a simplified ether is productive

with the inclusion of an ortho-methyl group.




**Figure 8.** X-ray co-crystal structure of ether **23** with USP7, highlighting key interactions

with the binding pocket. The PDB code for **23** bound to USP7 is 6VN3.

1  
2  
3  
4 This structural simplification enabled extensive SAR exploration of the basic  
5  
6  
7 amine portion of these molecules. Analogues were assessed based on their  
8  
9  
10 biochemical USP7 inhibition as well as in a cellular assay to measure elevated p53  
11  
12  
13 levels.<sup>18</sup> This was accomplished by utilizing a p53 response element-driven luciferase  
14  
15  
16 reporter assay in engineered RKO cells. In addition to pyrrolidines such as **23**, many  
17  
18  
19 other ring systems were well tolerated with respect to USP7 potency (Table 4). 3- and  
20  
21  
22 4-piperidinyll compounds such as **24** and **25** were both tolerated, as were azetidines  
23  
24  
25  
26 such as **26**. Even exocyclic amines such as cyclobutane **27** showed potent USP7  
27  
28  
29 inhibition. However, most of these compounds still demonstrated only moderate  
30  
31  
32 clearance and bioavailability. After screening many substituents on these ring systems,  
33  
34  
35  
36 it was found that a single methyl group afforded a drastic change in the PK profile of the  
37  
38  
39 4-substituted-piperidine set of compounds. Relative to piperidine **25**, methyl-piperidine  
40  
41  
42  
43 **28** had 5-fold lower rat IV clearance and 20-fold greater PO AUC. The methylated  
44  
45  
46  
47 compound **28** was also more potent in line with its greater lipophilicity relative to the  
48  
49  
50  
51 parent compound **25**.  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 4. Highlights of compounds in the simplified ether series



Compound d	R Group	USP7 IC <sub>50</sub> (nM) <sup>a,b</sup>	p53 EC <sub>50</sub> (nM) <sup>a,c</sup>	cLogP <sup>d</sup>	LipE <sup>e</sup>	IV clearance (L/hr/kg) <sup>f</sup>	PO AUC (hr*ng/mL) <sup>f</sup>
23		1.2	560	3.5	5.4	2.1	130
24		4.6	180	3.7	4.6	4.9	170
25		8.0	400	3.1	5.0	0.33	44
26		1.5	320	3.4	5.4	N.D.	N.D.
27		3.4	150	3.2	5.3	N.D.	N.D.
28		2.1	150	3.6	5.1	0.07	860

<sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.


<sup>c</sup>p53-reporter gene assay in RKO cells. <sup>d</sup>Calculated using ChemDraw. <sup>e</sup>LipE =  $\rho(\text{IC}_{50})$  -

1  
2  
3 cLogP. <sup>f</sup>Sprague-Dawley rats, dose of 0.5 mg/kg IV, 2 mg/kg PO. N.D. = not  
4  
5  
6  
7 determined.  
8  
9

### 10 11 *Re-examination of the Succinimide Side Chain* 12 13

14  
15 Having established this new piperidine ether as providing an improved PK profile  
16  
17  
18 relative to the benzofuran series, the succinimide side chain was re-evaluated. Although  
19  
20  
21 the succinimide was a key potency-driver, this moiety was also chemically labile and  
22  
23  
24 slowly hydrolyzed under aqueous conditions. Fortunately, substitution on the  
25  
26  
27 succinimide backbone with a cyclopropyl ring mitigated hydrolysis while maintaining  
28  
29  
30 potency (**29**, Table 5). Further succinimide substitution with a gem-dimethylcyclopropyl  
31  
32  
33 ring resulted in a compound with greater biochemical potency in line with an increase in  
34  
35  
36 lipophilicity (**30**), as well as with greatly enhanced chemical stability. Replacement of the  
37  
38  
39 succinimide for a substituted uracil as in **31** also resulted in a potent compound;  
40  
41  
42 however, the PK properties for uracil-containing compounds were sub-optimal, in part  
43  
44  
45 due to greater efflux.  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 **Table 5.** Cyclic imide SAR  
56  
57  
58  
59  
60



Compound d	R Group	USP7 IC <sub>50</sub> (nM) <sup>a,b</sup>	p53 EC <sub>50</sub> (nM) <sup>a,c</sup>	cLogP <sup>d</sup>	LipE <sup>e</sup>	IV clearance (L/hr/kg) <sup>f</sup>	PO AUC (hr*ng/mL) <sup>f</sup>
<b>28</b>		2.1	150	3.6	5.1	0.07	860
<b>29</b>		1.1	170	3.8	5.1	N.D.	N.D.
<b>30</b>		0.18	65	5.1	4.6	0.11	4700
<b>31</b>		0.26	42	4.2	5.4	1.0	52

<sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.

<sup>c</sup>p53-reporter gene assay in RKO cells. <sup>d</sup>Calculated using ChemDraw. <sup>e</sup>LipE =  $\rho(\text{IC}_{50})$  -

cLogP. <sup>f</sup>Sprague-Dawley rats, dose of 0.5 mg/kg IV, 2 mg/kg PO. N.D. = not determined.

1  
2  
3  
4 Out of the above compounds, gem-dimethylcyclopropylsuccinimide **30** had the  
5  
6  
7 best combination of potency and PK properties. Additionally, **30** was found to be potent  
8  
9  
10 against the MM.1S and H526 cell lines. It is well-established that the MM.1S cell line, a  
11  
12  
13 p53-wildtype multiple myeloma cell line, is sensitive to USP7 inhibition and other  
14  
15  
16 mechanisms of p53 activation.<sup>7,9</sup> Additionally, we have recently discovered that certain  
17  
18  
19 p53-mutant cancer cell lines are also sensitive to USP7 inhibitors, including H526, a  
20  
21  
22 small-cell lung cancer cell line.<sup>15</sup> This activity is presumably mediated through a different  
23  
24  
25 mechanism other than p53 elevation since the p53 pathway is expected to be non-  
26  
27  
28 functional in H526 cells.<sup>19</sup> Furthermore, target engagement was demonstrated for  
29  
30  
31 compound **30** in MM.1S cells, highlighting that our inhibitors are capable of preventing  
32  
33  
34 USP7 from binding and conjugating to an active-site ubiquitin probe.<sup>20</sup>  
35  
36  
37  
38  
39  
40  
41  
42


43 Compound **30** possessed significant cytotoxic activity against both the MM.1S  
44  
45  
46 and H526 cell lines, demonstrating a  $CC_{50}$  of 140 nM and 440 nM, respectively.  
47  
48  
49 Additionally, **30** was tested against a wide variety of DUBs and was found to have  
50  
51  
52 exquisite selectivity for USP7. Compound **30** showed an  $IC_{50}$  >10  $\mu$ M for all the >40  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 DUBs that were assayed, corresponding to a >50,000-fold selectivity for USP7 over the  
4  
5  
6  
7 other DUBs.<sup>21</sup> Unfortunately, **30** also exhibited some general cytotoxicity, observed by  
8  
9  
10 sharply reduced ATP levels at 3.4  $\mu\text{M}$  in RKO cells, suggestive of physicochemical  
11  
12  
13 toxicity. Additionally, substantial hERG inhibition was observed with this compound in a  
14  
15  
16 simple hERG binding assay (0.4  $\mu\text{M}$ ) as well as mild CYP3A4 inhibition (6.2  $\mu\text{M}$ ). These  
17  
18  
19 sub-optimal properties along with the above-mentioned cytotoxicity encouraged further  
20  
21  
22 SAR exploration into a somewhat different chemical space from ether-linked compound  
23  
24  
25  
26  
27  
28 **30**.

### 31 32 *Carbon-Linked Compounds Replace the Ether Series*

33  
34  
35  
36 The ether oxygen atom had been omnipresent in our USP7 inhibitors up to this  
37  
38  
39 point (first in the benzofurans and later in the simplified ethers) because it was assumed  
40  
41  
42 that the buried hydrogen bond to Tyr-465 (as observed in co-crystal structures with  
43  
44  
45 USP7) was critical for binding activity. The importance of this interaction, however, had  
46  
47  
48 never been experimentally established. Free Energy Perturbation (FEP+) calculations<sup>22</sup>  
49  
50  
51 had been successfully used throughout this program to assess different modifications in  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 order to help prioritize compounds, especially in occasions involving challenging or  
4  
5  
6  
7 lengthy syntheses. Using FEP+, the relative binding free energy was calculated for  
8  
9  
10 compounds where the ether oxygen had been replaced with a nitrogen or carbon atom.  
11  
12  
13  
14 Much to our surprise, carbon-linked analogues were predicted to be equipotent to the  
15  
16  
17 standard ether-linked compounds; nitrogen-linked analogues were predicted to be even  
18  
19  
20 more potent. These calculations were validated when aniline **33** and methylene-  
21  
22  
23 analogue **34** were synthesized and assayed (Figure 9). Compared to ether-linked  
24  
25  
26 compound **32**, carbon-linked compound **34** was slightly more potent. Nitrogen-linked  
27  
28  
29 compound **33** displayed marked improvements in potency, especially in the cellular p53  
30  
31  
32 assay. This phenomenon was rationalized by re-analyzing the USP7 crystal structure,  
33  
34  
35 which revealed a small hole on the side of the protein opposite to the ligand binding site  
36  
37  
38 which enables Tyr-465 to be solvent exposed.<sup>23</sup> This could help make up for loss of  
39  
40  
41 hydrogen bond when moving to the carbon-linker and enable additional hydrogen  
42  
43  
44 bonding when Tyr-465 switches from an H-bond donor to an H-bond acceptor when  
45  
46  
47 bound to aniline **33**.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



14 **Figure 9.** Biochemical and cellular potencies with oxygen-, nitrogen-, and carbon-linked  
15  
16  
17 compounds.  
18  
19

20  
21  
22 SAR of the new nitrogen-linked series showed that while these compounds were  
23  
24 quite potent, they had poor PK properties, likely in part due to an additional hydrogen-  
25  
26 bond donor. Additionally, this series was undesirable because it introduced an aniline  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


ether-linked compound **30**.

Initially, simple piperazine **35** was not a very potent compound (Table 6).  
However, the addition of methyl groups to the 2- and 6-positions of the piperazine ring

1  
2  
3 significantly influenced potency, as evidenced from the progression of piperazine **35** to  
4  
5  
6  
7 methyl piperazine **36** to di-methyl piperazine **37**. It is likely that these groups aid in  
8  
9  
10 reinforcing the U-shape required to properly position the basic amine in the binding  
11  
12  
13  
14 pocket. Dimethyl piperazine **37** displayed excellent PK with low clearance and a large  
15  
16  
17 PO exposure and showed a hERG IC<sub>50</sub> of 2.7 μM, almost a 10-fold improvement over  
18  
19  
20 ether **30**. However, cellular potencies against the MM.1S and H526 cell lines were sub-  
21  
22  
23  
24 optimal for compound **37**.  
25  
26  
27

28  
29 The morpholine series yielded extremely potent USP7 inhibitors (Table 6).  
30  
31  
32 Unsubstituted morpholine **38** demonstrated remarkable potency, displaying an  
33  
34  
35 enzymatic potency of 160 pM. As with the piperazine series, the reduced basicity and  
36  
37  
38 lipophilicity of morpholine **38** resulted in a further reduction in hERG inhibition,  
39  
40  
41 displaying an IC<sub>50</sub> of 8 μM. Unlike the piperazine series, the addition of methyl groups at  
42  
43  
44  
45 either the 3- or 6-positions did not result in a dramatic increase in potency (see  
46  
47  
48  
49 compounds **39** and **40**).  
50  
51  
52  
53

54 **Table 6.** Effects of methyl substitutions in the piperazine and morpholine series<sup>a</sup>  
55  
56  
57  
58  
59  
60



Compound d	R Group	Imide	USP7 IC <sub>50</sub> (nM) <sup>b</sup>	p53 EC <sub>50</sub> (nM) <sup>c</sup>	MM.1S CC <sub>50</sub> (nM) <sup>d</sup>	H526 CC <sub>50</sub> (nM) <sup>e</sup>	cLogP <sup>f</sup>	LipE <sup>g</sup>
<b>35</b>			32	1200	N.D.	N.D.	3.4	4.1
<b>36</b>			6.6	280	N.D.	N.D.	3.9	4.3
<b>37</b>			0.32	60	135	2200	4.4	5.1
<b>38</b>			0.16	35	210	3600	3.4	6.4
<b>39<sup>h</sup></b>			1.5	210	310	N.D.	3.9	4.9
<b>40<sup>h</sup></b>			0.39	60	120	N.D.	3.9	5.5

<sup>a</sup>Data represent the mean of  $n = 2$  or more determinations. <sup>b</sup>USP7 biochemical assay.


<sup>c</sup>p53-reporter gene assay in RKO cells. <sup>d</sup>Cytotoxicity assay in MM.1S cells. <sup>e</sup>Cytotoxicity

1  
2  
3 assay in H526 cells. <sup>f</sup>Calculated using ChemDraw. <sup>g</sup>LipE =  $\rho(\text{IC}_{50}) - \text{cLogP}$ . <sup>h</sup>Racemic  
4  
5  
6  
7 compound. N.D. = not determined.  
8  
9

### 10 11 *In Vivo Xenograft Studies* 12 13

14  
15 With these new promising piperazine and morpholine series, the most potent  
16  
17 cyclic imide side chains were re-evaluated. Among the compounds surveyed,  
18  
19 morpholine **41** demonstrated the optimal balance of cellular potencies and PK  
20  
21 properties and was selected for in vivo xenograft studies (Table 7). Several other  
22  
23 compounds (such as piperazine **37**) had excellent PK properties but lacked sufficient  
24  
25 potency in the MM.1S and H526 cellular assays. Compound **41** showed excellent  
26  
27 activity in cellular assays and maintained a good therapeutic index as demonstrated by  
28  
29 a high RKO CC<sub>50</sub>. While compound **41** displayed excellent PK properties in rat, murine  
30  
31 PK studies indicated that **41** had slightly worse oral exposure in NOD-SCID or nude  
32  
33 mice – animals required for the subsequent xenograft studies.<sup>24</sup> Consequently, an  
34  
35 elevated oral dose of 50 mg/kg BID was chosen for these in vivo efficacy studies.<sup>25</sup>  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54


55 **Table 7.** Properties of compound **41**.  
56  
57  
58  
59  
60



						PO AUC @ 30 mg/kg (hr*ng/mL)		
USP7 IC <sub>50</sub>	p53 EC <sub>50</sub>	MM.1S CC <sub>50</sub>	H526 CC <sub>50</sub>	RKO CC <sub>50</sub>	hERG IC <sub>50</sub>	Balb/C	NOD- SCID	Nude
0.44 nM	25 nM	89 nM	450 nM	13 μM	4.2 μM	9,400	5,500	4,600

The ability of compound **41** to suppress tumor growth was assessed in an MM.1S xenograft model using NOD-SCID mice. When given a 50 mg/kg oral dose of compound **41** twice daily, nearly complete tumor growth inhibition was observed (Figure 10a). This dose was generally well tolerated among the animals, but in the few cases where body weight dropped to less than 90% of their original weight, a dosing holiday was given. This resulted in a rebound of the animal's body weight, whereupon regular dosing was resumed.

1  
2  
3  
4 Tumor growth inhibition in the MM.1S xenograft model is suspected to be  
5  
6  
7 primarily mediated through increases in p53, but a subset of p53-mutant cell lines are  
8  
9  
10 also sensitive to USP7 inhibition.<sup>15</sup> Compound **41** inhibited the growth of p53-mutant  
11  
12  
13 small cell lung cancer cell line H526 at a  $CC_{50}$  of 450 nM, implying that tumor growth  
14  
15  
16 suppression might be observed in an in vivo setting. For the H526 xenograft model,  
17  
18  
19 athymic nude mice were administered twice daily oral doses of compound **41** for 24  
20  
21  
22 days (Figure 10b). At 50 mg/kg, significant tumor growth inhibition was observed which  
23  
24  
25  
26 resulted in strikingly improved survival as compared to the vehicle control group. Since  
27  
28  
29 compound **41** is less potent towards H526 cells than MM.1S cells in vitro, it is not  
30  
31  
32 surprising that there is slightly inferior tumor growth inhibition in the H526 xenograft  
33  
34  
35 model as compared to the MM.1S study. Nevertheless, this in vivo activity demonstrates  
36  
37  
38 that USP7 inhibitors can suppress tumor growth through multiple different pathways,  
39  
40  
41  
42 potentially widening the utility of USP7 inhibitors beyond p53-sensitive tumors.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 10.** Xenograft studies with (a) NOD-SCID mice engrafted with MM.1S tumors, or (b) athymic nude mice engrafted with H526 tumors. For each study, compound 41 was dosed PO at 50 mg/kg BID for the indicated time and tumor volume was measured. If the tumor volume exceeded 1500 mm<sup>3</sup>, the animals were taken down from the study (\*\*\*\*  $p < 0.0001$ ).

## SYNTHETIC CHEMISTRY

USP7 inhibitors were synthesized in a convergent manner by palladium-catalyzed coupling between the upper thienopyridine piece and the lower aryl portion. The thienopyridine pieces were synthesized according to Scheme 1. Commercial thienopyridine chloride **42** was elaborated to aldehyde **43** by trapping the corresponding lithium anion with DMF at low temperature.<sup>26</sup> Simple reduction of aldehyde **43** produced alcohol **44**, which could be converted to succinimidyl side chain **45** via chlorination and subsequent S<sub>N</sub>2 displacement. This piece could be borylated to produce boronic ester **46** for subsequent Suzuki coupling. Alternatively, alcohol **44** can be protected as the silyl ether **47** and borylated to produce **48**. The silyl ether moiety was useful for late-stage diversification of the imide side chain.

Scheme 1. Synthesis of thienopyridine pieces.




Reagents: (a) *n*-BuLi, -78 °C, DMF, 90%. (b) NaBH<sub>4</sub>, MeOH, 96%. (c) SOCl<sub>2</sub>, DCM,

1  
2  
3 99%. (d) pyrrolidine-2,5-dione, K<sub>2</sub>CO<sub>3</sub>, acetone, 63%. (e) B<sub>2</sub>Pin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>, dppf,  
4  
5  
6  
7 KOAc, dioxane, 110 °C, 83-99%. (f) TBS-Cl, imidazole, DMF, 85%.  
8  
9

10  
11 The benzofuran-amide portion was prepared from 2-bromo-4-chlorophenol (**49**,  
12  
13  
14 Scheme 2). Phenol **49** was allylated with allyl bromide and was converted to 2-  
15  
16  
17 allylphenol **50** by a Claisen rearrangement.<sup>27</sup> Epoxidation with *m*-CPBA afforded **51**,  
18  
19  
20 which underwent facile cyclization under basic conditions to afford alcohol **52**. TEMPO-  
21  
22  
23 catalyzed oxidation of **52** afforded the racemic carboxylic acid, which was  
24  
25  
26  
27  
28 enantioenriched to the (*R*)-acid **53** by classical resolution with naphthylamine **54**,  
29  
30  
31  
32 affording **53** in 99% ee on multi-gram scale. This enantioenriched acid was converted to  
33  
34  
35 piperazine-amide **55** by T3P coupling. This compound could be converted to the aryl  
36  
37  
38  
39 stannane **56** for subsequent Stille coupling. The final products were prepared via one of  
40  
41  
42  
43 two protocols – via Stille coupling of chloropyridine **57** and stannane **56** followed by  
44  
45  
46 acidic deprotection, or via Suzuki coupling of pyridine boronic ester **58** and aryl bromide  
47  
48  
49  
50 **55** followed by deprotection under acidic conditions.  
51  
52  
53

54 **Scheme 2.** Synthesis of benzofuran-amide USP7 inhibitors.  
55  
56  
57  
58  
59  
60




(a) allyl bromide,  $K_2CO_3$ , acetone, 55 °C. (b) mesitylene, 180 °C, 73% over 2 steps. (c) *m*-CPBA, DCM. (d) KOH, MeOH/H<sub>2</sub>O. (e) TEMPO (cat.), KBr (cat.), NaOCl, NaHCO<sub>3</sub>, THF, H<sub>2</sub>O, 0°C (52% over 3 steps). (f) **54**, MeOH, recrystallization (x2), 42%. (g) *N*-Boc-piperazine, 1-methylimidazole, propanephosphonic anhydride, EtOAc, 81%. (h) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (cat.), (Sn(*n*-Bu)<sub>3</sub>)<sub>2</sub>, 1,4-dioxane, 110 °C, 72%. (i) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Cu<sub>2</sub>O, 1,4-dioxane, 100 °C. (j) HCl or TFA, DCM, 90-99%. (k) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, aq. Na<sub>2</sub>CO<sub>3</sub>, EtOH, PhMe, 85 °C.

To prepare the simplified ether analogues, phenol **60** and substituted alcohol **61** were brought together in a Mitsunobu reaction to form ether **62** (Scheme 3). Suzuki

1  
2  
3  
4 coupling with boronic ester **46** followed by protecting group removal afforded the final  
5  
6  
7 compound **63**. Analogs with diverse imide side chains could also be generated by late-  
8  
9  
10 stage substitution via intermediates such as TBS-ether **64**. Accordingly, Suzuki coupling  
11  
12  
13 of aryl bromide **62** with boronic ester **48** yielded coupled product **64**. Silyl cleavage  
14  
15  
16 followed by chlorination with methanesulfonyl chloride enabled facile displacement by a  
17  
18  
19 range of cyclic imides or other nucleophiles. Deprotection under acidic conditions  
20  
21  
22 produced the final compounds.  
23  
24  
25  
26  
27  
28

29 **Scheme 3.** Synthesis of the simplified ether series of compounds.  
30  
31  
32



Reagents: (a)  $\text{PPh}_3$ , DIAD, THF, 51-80%. (b) **46**,  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ , aq.  $\text{Na}_2\text{CO}_3$ , EtOH,


PhMe, 85 °C, 20-69%. (c) TFA or HCl, DCM, 90-99%. (d) **48**,  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ , aq.

1  
2  
3 Na<sub>2</sub>CO<sub>3</sub>, EtOH, PhMe, 85 °C, 21-61%. (e) TBAF, THF, 67-94%. (f) MsCl, DIPEA, DCM,  
4  
5  
6  
7 then cyclic imide, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 60 °C, 45-65%.  
8  
9

10  
11         Synthesis of the piperazine series of inhibitors is outlined in Scheme 4. Starting  
12  
13 from 4-chloro-2-methylbenzoic acid (**66**), large amounts of benzyl bromide **67** could be  
14  
15 prepared via a 3-step sequence of carboxylate-directed C–H iodination, reduction, and  
16  
17 bromination. Treatment of benzyl bromide **67** with mono-Boc-protected piperazine **68**  
18  
19 and sodium hydride afforded benzylic piperazine **69**. Suzuki coupling with boronic ester  
20  
21 **46** followed by deprotection afforded the final compounds.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33         The morpholine-containing compounds were synthesized through alkylation of  
34  
35 PMB-protected morpholinone **71** with benzyl bromide **67**, followed by lactam reduction  
36  
37 to give racemic morpholine **72** (Scheme 4). Protecting group exchange from PMB to  
38  
39 Boc and then chiral separation afforded chiral morpholine **73**. Suzuki coupling with  
40  
41 boronic ester **46** followed by deprotection gave the final compounds.  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 **Scheme 4.** Synthesis of carbon-linked compounds: piperazines and morpholines.  
52  
53  
54  
55  
56  
57  
58  
59  
60




Reagents: (a) NIS, Pd(OAc)<sub>2</sub>, DMF, 120 °C, 30%. (b) borane-DMS, THF, 50 °C, 73%. (c) PBr<sub>3</sub>, DCM, 88%. (d) NaH, DMF, 42-83%. (e) **46**, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, aq. Na<sub>2</sub>CO<sub>3</sub>, EtOH, PhMe, 85 °C, 20-69%. (f) TFA, or HCl, DCM 90-99%. (g) LDA, THF, -78 °C, 43-62%. (h) borane-THF, THF, 70 °C, 62-88%. (i) chloroethyl chloroformate, DCE, then MeOH, 70 °C, 84-98%. (j) Boc<sub>2</sub>O, imidazole, THF, 63-99%. (k) chiral SFC separation.

In order to synthesize multi-gram quantities of compound **41** for in vivo studies, an improved synthetic route to enantiopure morpholine **79** was designed (Scheme 5). Readily available 2-bromo-4-chloro-6-methylaniline (**75**) was first converted to epoxide **76** through a two-step procedure of allylation<sup>28</sup> followed by epoxidation. Epoxide **76** could be opened regioselectively with ethanolamine to give amino-diol **77**. Boc protection followed by Mitsunobu ring closure and treatment with HCl afforded racemic morpholine **78**. From epoxide **76**, morpholine **78** can be accessed in 59% yield over 4

1  
2  
3 steps without column chromatographic purification. Neutralization of the HCl salt  
4  
5  
6  
7 generated the morpholine free base which was utilized to develop a large-batch  
8  
9  
10 resolution/recrystallization procedure. The addition of 0.5 equivalents of *N*-Ac-D-Leu  
11  
12  
13 allowed for enrichment of the desired morpholine enantiomer, and repeated  
14  
15  
16  
17 recrystallization followed by Boc protection enabled production of chiral morpholine **79**  
18  
19  
20  
21 in 99% ee on multi-gram scale. Standard Suzuki coupling with boronic ester **48** afforded  
22  
23  
24 compound **80** that was converted into compound **41** by silyl cleavage, chlorination,  
25  
26  
27 displacement with 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione, and deprotection  
28  
29  
30  
31 under acidic conditions.  
32  
33  
34  
35

36 **Scheme 5.** Synthetic route to access multi-gram quantities of enantiopure compound  
37  
38  
39 **41.**  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



21 Reagents: (a) allyl bromide,  $t\text{BuONO}$ , MeCN, 73%. (b)  $m\text{CPBA}$ , DCM, 63%. (c) ethanol  
22  
23 amine, THF, 60 °C. (d)  $\text{Boc}_2\text{O}$ , imidazole, THF. (e) DIAD,  $\text{PPh}_3$ , MTBE. (f) HCl, DCM,  
24  
25  
26  
27 59% over 4 steps. (g) NaOH, DCM. (h) *N*-Ac-D-Leu (0.5 equiv), DCE, recrystallization  
28  
29  
30  
31 (x3). (i)  $\text{Boc}_2\text{O}$ ,  $\text{Et}_3\text{N}$ , DCM, 31% over 3 steps. (j) **48**,  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ ,  $\text{Na}_2\text{CO}_3$ , EtOH,  
32  
33  
34 PhMe, 85 °C. (k) TBAF, THF, 78% over 2 steps. (l) MsCl, DIPEA, DCM, then 6,6-  
35  
36  
37 dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione,  $\text{Cs}_2\text{CO}_3$ , MeCN, 60 °C. (m) HCl, DCM, 65%  
38  
39  
40  
41 over 2 steps.  
42  
43  
44  
45  
46  
47  
48  
49

## 50 CONCLUSION

51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Co-crystal structures of USP7 with two micromolar inhibitors of different  
5  
6  
7 chemotypes revealed both compounds bound to the same allosteric site adjacent to the  
8  
9  
10 catalytic site of the enzyme. Careful analysis of the binding of a novel pyridylbenzofuran  
11  
12  
13 series suggested possibilities for establishing additional interactions and displacing  
14  
15  
16 unfavorable water molecules within this site. Introduction of a succinimide side chain to  
17  
18  
19 a thienopyridine functionality resulted in significantly increased potency. In order to  
20  
21  
22 improve the pharmacokinetic properties of these inhibitors, non-benzofuran chemotypes  
23  
24  
25 were developed. Key to this success was the re-design of the benzofuran-amide  
26  
27  
28 template to a simplified ortho-methyl ether series of compounds employing acyclic  
29  
30  
31 conformational control. Drug-like properties and cellular potencies were further  
32  
33  
34 improved by switching from ether-linked compounds to carbon-linked piperazines and  
35  
36  
37 morpholines, leading to the discovery of compound **41**. This USP7 inhibitor  
38  
39  
40 demonstrates marked tumor growth inhibition in both p53-wild type and p53-mutant  
41  
42  
43 tumors, suggesting that USP7 inhibition can suppress tumor growth in vivo through both  
44  
45  
46 p53 dependent and independent mechanisms. Further elucidation of these intricate  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 pathways could delineate a future clinical pathway for these potent, selective, and orally  
4  
5  
6  
7 bioavailable USP7 inhibitors.  
8  
9  
10  
11  
12  
13  
14

## 15 EXPERIMENTAL SECTION

16  
17  
18  
19

### 20 General Chemistry.

21

22 All chemicals were purchased from commercial suppliers and used as received. An  
23 inert atmosphere of nitrogen or argon was used for reactions involving air or moisture  
24 sensitive reagents. Analytical thin layer chromatography (TLC) was performed using  
25 2.5 x 7.5 cm Merck silica gel 60 F<sub>254</sub> thin layer plates (EMD Millipore 1.15341.0001)  
26 visualized using combinations of UV visualization, p-anisaldehyde, potassium  
27 permanganate, and/or iodine staining. Silica gel column chromatography was performed  
28 using Teledyne ISCO RediSep Rf normal phase (35–70 μm) silica gel columns on a  
29 Teledyne ISCO CombiFlash Rf or CombiFlash Rf+ purification system (detection at 254  
30 nm). Reversed-phase preparative HPLC was carried out using a Gemini-NX-C18  
31 column (10 μm, 250 x 30 mm, Phenomenex, Torrance, CA) eluting with a linear gradient  
32 from 5 to 100% acetonitrile in water containing 0.1% trifluoroacetic acid over 30 minutes  
33 on a Teledyne ISCO EZ Prep, Teledyne ISCO ACCQPrep HP125, or Agilent 1200  
34 Series purification system. Analytical reverse phase HPLC was performed using a  
35 Gemini-NX-C18 column (5 μm, 250 x 4.6 mm, Phenomenex, Torrance, CA) eluting with  
36 MeCN in water with 0.1% TFA on an Agilent 1200 Series purification system (detection  
37 at 254 nm). Proton NMR spectra were recorded on a Varian Oxford 400 MHz  
38 spectrometer and carbon NMR spectra were recorded at 101 MHz. Chemical shifts are  
39 expressed in δ ppm referenced to tetramethylsilane (δ = 0 ppm). Abbreviations used in  
40 describing peak signal multiplicity are as follows: s = singlet, d = doublet, dd = double  
41 doublets, t = triplet, q = quartet, m = multiplet, br = broad peak. Analytical LC-MS was  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 performed using a ZORBAX SB-C18 column (1.8  $\mu\text{m}$ , 2.1 x 50 mm, 600 bar, Agilent,  
5 Santa Clara, CA) eluting with a linear gradient from 0% to 100% B over 2 min and then  
6 100% B for 3 min (A = 5% MeCN in H<sub>2</sub>O with 0.1% formic acid, B = MeCN + 0.1%  
7 formic acid, flow rate 0.4 mL/min) using an Agilent 1260 Infinity II LC System (detection  
8 at 254 nm) equipped with an Agilent 6120 Quadrupole LC/MS in electrospray ionization  
9 mode (ESI+). The purity of all compounds used in bioassays was determined by this  
10 method to be >95% pure.  
11  
12  
13  
14  
15

16 **7-chlorothieno[3,2-b]pyridine-2-carbaldehyde (43)**. To a solution of 7-chlorothieno[3,2-  
17 b]pyridine (65.2 g, 0.384 mol) in anhydrous THF (0.64 L, 0.6 M) at  $-78\text{ }^{\circ}\text{C}$  was added a  
18 solution of *n*-BuLi (0.2 L, 0.5 mol, 1.3 equiv.) over 0.5 hr using an addition funnel. The  
19 mixture was stirred at  $-78\text{ }^{\circ}\text{C}$  for 2 hr before the addition of DMF (98 mL, 1.27 mol, 3.3  
20 equiv.). The mixture was stirred for an additional 2 hr before warming to  $0\text{ }^{\circ}\text{C}$ . 2 N aq.  
21 HCl (0.8 L) was added to acidify the mixture. The resulting precipitate was collected by  
22 filtration and dried in vacuo to yield the desired product as a yellow solid (68.5 g, 90%  
23 yield).  
24  
25  
26  
27  
28  
29

30 **(7-chlorothieno[3,2-b]pyridin-2-yl)methanol (44)**. To a stirred suspension of aldehyde **43**  
31 (73.7 g, 0.373 mol) in methanol (1.1 L, 0.33 M) at  $0\text{ }^{\circ}\text{C}$  was carefully added NaBH<sub>4</sub> (28.2  
32 g, 0.746 mol, 2 equiv.) in portions over 30 min. The mixture was allowed to stir for an  
33 additional 30 min at  $0\text{ }^{\circ}\text{C}$ . The reaction was monitored by LCMS to completion, and the  
34 mixture was concentrated in vacuo. The residue was triturated with H<sub>2</sub>O (1 L) and the  
35 resulting solid was collected by filtration and dried in vacuo to yield the desired product  
36 (71.6 g, 96% yield). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.54 (d,  $J$  = 5.1 Hz, 1H), 7.44  
37 (t,  $J$  = 1.1 Hz, 1H), 7.26 (d,  $J$  = 5.2 Hz, 1H), 5.01 (d,  $J$  = 1.1 Hz, 2H). [M+H] 200.0.  
38  
39  
40  
41  
42  
43  
44

45 **1-((7-chlorothieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (45)**. To a stirred  
46 suspension of alcohol **44** (21.6 g, 108.2 mmol) in dichloromethane (200 mL) was added  
47 SOCl<sub>2</sub> (23.5 mL, 324.6 mmol, 3.0 equiv.) at room temperature. The mixture was stirred  
48 at room temperature for 20 h. Upon completion, the mixture was concentrated in vacuo  
49 to afford the desired chloride (27.5 g, 99% yield). To a stirred suspension of this alkyl  
50 chloride (7.0 g, 32.1 mmol) and K<sub>2</sub>CO<sub>3</sub> (17.74 g, 128.4 mmol, 4.0 equiv.) in acetone  
51 (215 mL) was added pyrrolidine-2,5-dione (7.0 g, 70.6 mmol, 2.2 equiv.). The mixture  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 was heated to 80 °C and stirred for 24 h and cooled to room temperature. The mixture  
5 was then filtered over celite, rinsing with 10% MeOH in DCM. The filtrate was  
6 concentrated in vacuo and purified by flash column chromatography (30-80% ethyl  
7 acetate/DCM) to afford the desired product as a white solid (5.7 g, 63% yield). <sup>1</sup>H NMR  
8 (400 MHz, Chloroform-*d*) δ 8.56 (d, *J* = 5.1 Hz, 1H), 7.55 (t, *J* = 0.8 Hz, 1H), 7.26 (d, *J* =  
9 5.0 Hz, 1H), 4.96 (s, 2H), 2.78 (s, 4H). [M+H] 281.0.

10  
11  
12  
13  
14 **1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-**  
15 **yl)methyl)pyrrolidine-2,5-dione (46).** To thienopyridine chloride **45** (185 mg, 0.66 mmol),  
16 bis(pinacolato)diboron (160 mg, 0.6 mmol), Pd(dppf)Cl<sub>2</sub> (44 mg, 0.06 mmol), and  
17 potassium acetate (176 mg, 1.8 mmol) was added 1,4-dioxane (3 mL). The resulting  
18 mixture was heated to 100 °C for 3 h. The reaction mixture was diluted with water (5  
19 mL), extracted with EtOAc (2x), dried over sodium sulfate, filtered, and concentrated  
20 under reduced pressure to afford the title compound (161 mg, 99% yield) which was  
21 used directly for the next Suzuki coupling (general procedure B).  
22  
23  
24  
25  
26  
27  
28

29 **2-(((tert-butyldimethylsilyl)oxy)methyl)-7-chlorothieno[3,2-b]pyridine (47).** Alcohol **44** (30  
30 g, 150.3 mmol) was suspended in DCM (500 mL) followed by the addition of DIEA (105  
31 mL, 601.2 mmol), TBSCl (49.8 g, 330.6 mmol), and DMAP (3.67 g, 30 mmol). The  
32 mixture was allowed to stir at room temperature for 16 hrs. Upon completion, MeOH  
33 (100 mL) was added to the mixture and stirred for 2 hrs at room temperature. The  
34 reaction mixture was concentrated in vacuo and dissolved in DCM (500 mL). The  
35 organic layer was washed with 2N HCl (2 x 200 mL), H<sub>2</sub>O (1 x 200 mL), and brine (1 x  
36 200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give  
37 the product (40.2 g, 85%).  
38  
39  
40  
41  
42  
43  
44

45 **2-(((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-**  
46 **yl)thieno[3,2-b]pyridine (48).** Thienopyridine chloride **47** (40.2 g, 128.1 mmol),  
47 bis(pinacolato)diboron (65 g, 256.1 mmol), potassium acetate (37.7 g, 384.3 mmol), and  
48 Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (4.7 g, 6.4 mmol) were suspended in dioxane (173 mL). The mixture was  
49 degassed by bubbling with N<sub>2</sub> for 30 mins then heated to 100 °C for 4.5 hrs. Upon  
50 completion, the mixture was cooled to room temperature then MeOH (200 mL) was  
51 added. The mixture was stirred at room temperature for 1 hr before slowly poured into  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 water (1 L) with vigorous stirring. The solid was filtered and triturated with hexanes  
5 yielding the product (20.8 g). The hexane layer was concentrated in vacuo and the  
6 resulting solid was triturated with hexanes yielding the product (22.2 g, combined yield  
7 83%).  
8  
9

10  
11 **2-allyl-6-bromo-4-chlorophenol (50)**. To a solution of 2-bromo-4-chlorophenol (300 g,  
12 1.45 mol) in acetone (0.6 L) was added allyl bromide (184 g, 1.05 equiv.) and K<sub>2</sub>CO<sub>3</sub>  
13 (220 g, 1.1 equiv.). The mixture was stirred at 55 °C for 2 hr, then cooled to room  
14 temperature. The mixture was filtered and washed with acetone (0.6 L). The filtrate was  
15 dried and concentrated to afford the desired allylated product as an oil (358 g), which  
16 was used directly in the following step. This oil (358 g) was dissolved in mesitylene (80  
17 mL) and stirred at 180 °C for 24 hr. The mixture was cooled to room temperature and  
18 the mesitylene was removed by concentration in vacuo. The desired product was  
19 isolated by distillation (90-95 °C @ 1 torr) to afford the product as a colorless oil (262 g,  
20 73% over 2 steps).  
21  
22  
23  
24  
25  
26  
27  
28

29 **2-bromo-4-chloro-6-(oxiran-2-ylmethyl)phenol (51)**. To a solution of alkene **50** (180 g,  
30 0.73 mol) in DCM (800 mL) at 0 °C was added *m*-CPBA (263 g, 1.05 equiv.) in portions.  
31 The mixture was allowed to stir at room temperature overnight. The reaction was  
32 quenched with 2M aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and half sat. aq. NaHCO<sub>3</sub> with stirring. The  
33 organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to  
34 afford the product (190 g), which was used directly in the following step.  
35  
36  
37  
38  
39

40 **(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl)methanol (52)**. To a stirred solution of  
41 oxirane **51** (180 g) in methanol (800 mL) and water (50 mL) was added solid KOH (42 g,  
42 1.1 equiv.) in portions. The mixture was stirred at room temperature overnight. The  
43 mixture was concentrated under reduced pressure, diluted with water (800 mL) and  
44 ethyl acetate (800 mL), and acidified to ~pH 2 with 6N aq. HCl. The organic layer was  
45 washed with water, sat. aq. NaHCO<sub>3</sub>, and brine. The organic layer was dried over  
46 sodium sulfate and concentrated in vacuo to afford the product (190 g) which was used  
47 directly in the following step.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (*rac*-53).** To a solution of  
5 alcohol **52** (180 g, 0.68 mol) in THF (600 mL) and sat. aq. NaHCO<sub>3</sub> (600 mL) at 0 °C  
6 was added TEMPO (21.6 g, 0.2 equiv.) and potassium bromide (16.2 g, 0.2 equiv.).  
7 13% aq. NaOCl (900 mL, 3.0 equiv.) was then added dropwise via addition funnel to the  
8 stirred mixture. The mixture was warmed to room temperature, and the reaction was  
9 monitored by TLC. After 8 hr, the mixture was diluted with MTBE (500 mL), water (800  
10 mL), and 2M aq. potassium carbonate (100 mL), and the organic layer was removed.  
11 The aqueous layer was acidified to pH 2 with 6M aq. HCl, and the mixture was  
12 extracted with MTBE (2 x 500 mL). The organic extracts were dried over sodium sulfate,  
13 filtered, and concentrated in vacuo. The residue was triturated with a mixture of  
14 MTBE/hexanes (1:5) and collected by filtration to afford the desired racemic acid as an  
15 off-white solid (105 g, 52% over 3 steps).  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 **(*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (53).** To a solution of  
26 racemic acid *rac*-**53** (155 g, 0.56 mol) in methanol (500 mL) was slowly added a solution  
27 of (*S*)-1-(naphthalen-1-yl)ethan-1-amine (101 g, 0.59 mol, 1.05 equiv.) in methanol (500  
28 mL). The resulting salt (255 g) was recrystallized from hot methanol (3 L) to afford an  
29 isomerically enriched salt (100 g) after collecting the solid by filtration. The filtrate was  
30 concentrated and recrystallized from methanol to afford a second crop of isomerically  
31 enriched salt (20 g). The combined salts (120 g) were treated with 1 N aq. NaOH (200  
32 mL) and washed with MTBE (2 x 200 mL). The aqueous layer was acidified to pH 2 and  
33 extracted with EtOAc (2 x 200 mL). The combined organics were washed with water,  
34 brine, dried over sodium sulfate and concentrated to afford the title enantioenriched acid  
35 as a white solid (65 g, 42% yield, 99% ee).  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **tert-butyl (*R*)-4-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carbonyl)piperazine-1-**  
46 **carboxylate (55).** To a suspension of (*R*)-acid **53** (4.16 g, 15 mmol), N-Boc-piperazine  
47 (3.07 g, 16.5 mmol) and methylimidazole (3.59 mL, 45 mmol) in EtOAc (30 mL) was  
48 added a solution of T3P (50% by wt. in EtOAc, 17.9 mL, 30 mmol). The reaction mixture  
49 was stirred at room temperature overnight. The reaction mixture was diluted with aq.  
50 NaOH solution (1M, 150 mL), extracted with EtOAc (2 x 100 mL), dried over sodium  
51 sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash  
52  
53  
54  
55  
56  
57  
58  
59  
60

column chromatography (20-100% EtOAc in hexanes) to afford the title compound (5.4 g, 81% yield). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 7.27 (s, 1H), 7.12 (s, 1H), 5.47 (dd, *J* = 9.9, 6.6 Hz, 1H), 4.05 (dd, *J* = 16.2, 6.6 Hz, 1H), 3.99 – 3.89 (m, 2H), 3.81 – 3.63 (m, 2H), 3.53 – 3.18 (m, 5H), 1.48 (s, 9H). [M+Na] 467.0.

**tert-butyl (R)-4-(5-chloro-7-(tributylstannyl)-2,3-dihydrobenzofuran-2-carbonyl)piperazine-1-carboxylate (56).** A solution of aryl bromide **55** (3.0 g, 6.73 mmol) and bis(triphenylphosphine)palladium (II) chloride (236 mg, 0.337 mmol) in dioxane (67 mL) was evacuated/backfilled with argon (3x). To this mixture was added tributyl(tributylstannyl)stannane (5.86 g, 10.1 mmol). The resulting mixture was stirred at 110 °C for 18 h. The reaction mixture was allowed to cool to room temperature and solvent was removed under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc in hexanes) to afford the title compound (3.2 g, 72% yield) as a clear oil. [M+H] 657.0.

**General Procedure A (Stille Coupling).** To a solution of stannane **56** (0.23 mmol) and appropriate chloropyridine (for example, **45**, **47**, or **57**, 0.23 mmol) in 1,4-dioxane (1.5 mL) was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (16 mg, 0.02 mmol) and copper oxide (33 mg, 0.23 mmol). The resulting mixture was sparged with argon for 5 min and heated to 100 °C with stirring for 6 h. The solvent was removed under reduced pressure and the crude residue was purified by flash column chromatography (0-10% MeOH in DCM) to afford the coupled product.

**General Procedure B (Suzuki Coupling).** A mixture of pyridine boronic ester (for example, **46**, **48**, or **58**, 0.86 mmol), appropriate aryl bromide or iodide (for example, **55**, **62**, **69**, **73**, or **79**, 0.86 mmol), dichlorobis(triphenylphosphine)palladium(II) (60 mg, 0.09 mmol), and 1M aqueous sodium carbonate (2.5 mL) in toluene:ethanol (5 mL, 1:1 v/v) was heated to 85 °C and stirred vigorously for 1-15 h. The reaction mixture was diluted in EtOAc (40 mL), then water (20 mL) and brine (20 mL) were added and the organic layer was separated, dried over MgSO<sub>4</sub>, and concentrated. The crude residue was purified by column chromatography (0-10% MeOH in DCM) to afford the coupled product.

**General Procedure C (Boc-Deprotection with HCl).** Desired Boc-amine (0.7 mmol) was dissolved in DCM (4 mL), then HCl (4M in dioxane, 2 mL) was added. The resulting mixture was stirred at room temperature until complete conversion was achieved (1-3 h). The solvents were then removed in vacuo and residue was dried on high vacuum for 12 h to afford the final compound as the HCl salt.

**General Procedure D (Boc-Deprotection with TFA).** Desired Boc-amine (0.63 mmol) was dissolved in DCM (6 mL) at which time trifluoroacetic acid (1 mL) was added dropwise. The resulting mixture was stirred at room temperature until complete conversion was reached (1-3 h). The solvents were removed in vacuo and residue was dried on high vacuum for 12 h to afford the final compound as the TFA salt. If necessary, purification by reverse phase chromatography (0-100% MeCN in water) was performed.

**General Procedure E (Preparation of Free Bases).** The desired hydrochloride or TFA salt was dissolved in MeOH/DCM (20/80, 2mL) and filtered through a PL-HCO<sub>3</sub> MP SPE column, eluting with MeOH/DCM (20/80). The solvents were removed in vacuo and residue was dried on high vacuum for 12 h to afford the final compound as the free base.

**(7-(2-Aminopyridin-4-yl)-5-chloro-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (7).** The title compound was synthesized following general procedure B with tert-butyl 4-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carbonyl)piperazine-1-carboxylate (*rac-55*) and 2-aminopyridine-4-boronic acid pinacol ester followed by general procedure C to give the desired compound as the HCl salt (20 mg, 50% yield). <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm 7.87 (d, *J* = 6.9 Hz, 1H), 7.50 (d, *J* = 2.1 Hz, 1H), 7.45 – 7.39 (m, 2H), 7.33 (dd, *J* = 6.9, 1.7 Hz, 1H), 5.88 (dd, *J* = 9.9, 6.6 Hz, 1H), 4.04 – 3.75 (m, 4H), 3.65 – 3.54 (m, 2H), 3.39 – 3.26 (m, 4H). [M+H] 359.1.

**(5-chloro-7-(1H-pyrrolo[2,3-b]pyridin-4-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (8).** The title compound was synthesized following general procedure B with tert-butyl 4-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carbonyl)piperazine-1-carboxylate (*rac-55*) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-

b]pyridine followed by general procedures C and E to give the desired compound as the free base (25 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm 8.23 (bs, 1H), 7.43 (d, *J*=3.6Hz, 1H), 7.40 (d, *J*=2Hz, 1H), 7.32 (s, 1H), 7.28 (s, 1H), 6.55 (d, *J*=3.6Hz, 1H), 5.69 (dd, *J*=9.6, 6.8Hz, 1H), 3.76-2.56 (m, 10H). [M+H] 383.0.

**(*R*)-(5-chloro-7-(1H-pyrrolo[2,3-*b*]pyridin-4-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (9).** The title compound was synthesized following general procedure B with tert-butyl (*R*)-4-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carbonyl)piperazine-1-carboxylate (**55**) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-*b*]pyridine followed by general procedure C to give the desired compound as the HCl salt (165 mg, 0.431 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.44 (d, *J*=6.2 Hz, 1H), 7.81 (d, *J*=6.1 Hz, 1H), 7.74 (d, *J*=3.6 Hz, 1H), 7.56 (d, *J*=2.2 Hz, 1H), 7.47 (s, 1H), 7.03 (d, *J*=3.6 Hz, 1H), 5.91 – 5.81 (m, 1H), 4.02 – 3.76 (m, 4H), 3.77 – 3.69 (m, 1H), 3.61 – 3.54 (m, 1H), 3.43 – 3.04 (m, 4H). [M+H] 383.0.

**(*R*)-(5-chloro-7-(thieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (10).** The title compound was synthesized following general procedure A with tert-butyl 4-[5-chloro-7-tributylstannyl-2,3-dihydrobenzofuran-2-carbonyl]piperazine-1-carboxylate (**56**) and 7-chlorothieno[3,2-*b*]pyridine and purified by reverse phase HPLC using water (0.1% TFA) and acetonitrile (0.1% TFA) as the eluent followed by general procedure D to give the desired compound as the TFA salt (2.5 mg, 4% yield). <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>, hydrochloric acid salt): δ ppm 8.64 (s, 1H), 8.21 (bs, 1H), 7.86 (bs, 1H), 7.22 (bs, 1H), 7.67 (bs, 1H), 7.53 (s, 1H), 5.89 (m, 1H), 3.86-3.09 (m, 10H). [M+H] 400.0.

**[(2*R*)-5-chloro-7-(2-methylthieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-yl]-piperazin-1-yl-methanone (11).** The title compound was synthesized following general procedure A with tert-butyl 4-[5-chloro-7-tributylstannyl-2,3-dihydrobenzofuran-2-carbonyl]piperazine-1-carboxylate (**56**) and 7-chloro-2-methyl-thieno[3,2-*b*]pyridine followed by general procedure C. The title compound was isolated by flash column chromatography (silica gel, 0-10% MeOH in DCM + 0.1M NH<sub>3</sub>) (14 mg, 29% yield). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 8.61 (d, *J* = 4.9 Hz, 1H), 7.44 (d, *J* = 2.1 Hz, 1H), 7.36 – 7.19 (m, 3H), 5.46 (dd, *J* = 9.9, 7.1 Hz, 1H), 4.06 – 3.89 (m, 1H), 3.89 – 3.70 (m, 1H),

3.70 – 3.53 (m, 1H), 3.48 – 3.29 (m, 2H), 2.93 – 2.82 (m, 1H), 2.82 – 2.67 (m, 1H), 2.63 (s, 3H), 2.60 – 2.46 (m, 1H), 2.46 – 2.00 (m, 2H). [M+H] 414.1.

**(*R*)-(5-chloro-7-(2-(hydroxymethyl)thieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (12).** The title compound was synthesized following general procedure A with tert-butyl 4-[5-chloro-7-tributylstannyl-2,3-dihydrobenzofuran-2-carbonyl]piperazine-1-carboxylate (**56**) and (7-chlorothieno[3,2-*b*]pyridin-2-yl)methanol and purified by reverse phase HPLC using water (0.1% TFA) and acetonitrile (0.1% TFA) as the eluent followed by general procedures D and E successively to yield the desired compound as the free base. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm 8.75 (d, *J*=4.4Hz, 1H), 7.63 (d, *J*=4.8Hz, 1H), 7.61 (d, *J*=2.0Hz, 1H), 7.57 (s, 1H), 7.54 (d, *J*=2.0Hz, 1H), 5.88 (dd, *J*=9.6, 6.8Hz, 1H), 5.06 (s, 2H), 3.92-3.40 (m, 6H), 2.92-2.70 (m, 4H). [M+H] 430.0.

**(*R*)-(5-chloro-7-(2-(3-hydroxyoxetan-3-yl)thieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (13).** Step 1: To a solution of 7-chlorothieno[3,2-*b*]pyridine (1.0 g, 5.9 mmol) in THF (20 mL) at -78 °C was added a solution of *n*-BuLi (2.5M in hexanes, 1.3 equiv, 3.1 mL). The solution was stirred for 20 min before the addition of 3-oxetanone (850 mg, 11.8 mmol, 2.0 equiv). The solution was allowed to stir for 1 hr prior to quenching with sat. aq. NH<sub>4</sub>Cl (50 mL). The mixture was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were dried, filtered, and concentrated to afford a crude compound, which was recrystallized from 80% ethyl acetate in hexanes to afford 3-(7-chlorothieno[3,2-*b*]pyridin-2-yl)oxetan-3-ol as white crystals (1.12 g, 79% yield). [M+H] 242.0. Step 2: The title compound was synthesized following general procedure A with 3-(7-chlorothieno[3,2-*b*]pyridin-2-yl)oxetan-3-ol and stannane **56** followed by general procedure D to give the desired compound as the TFA salt (31 mg, 43% yield). [M+H] 472.0.

**((2*R*)-5-chloro-7-(2-(1-chloro-2,3-dihydroxypropan-2-yl)thieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-yl)(piperazin-1-yl)methanone (14).** The title compound was synthesized following general procedures A with stannane **56** and 3-(7-chlorothieno[3,2-*b*]pyridin-2-yl)oxetan-3-ol followed by general procedure C to give the desired compound as the HCl salt (27 mg, 30% yield). [M+H] 507.9.

1  
2  
3  
4 **(*R*)-3-((7-(5-chloro-2-(piperazine-1-carbonyl)-2,3-dihydrobenzofuran-7-yl)thieno[3,2-**  
5 **b]pyridin-2-yl)methyl)pyrimidin-4(3H)-one (15).** Step 1: 7-chloro-2-  
6 (chloromethyl)thieno[3,2-b]pyridine (300 mg, 1.38 mmol) was dissolved in DMF (9.2  
7 mL), then 1H-pyrimidin-6-one (264 mg, 2.75 mmol) and potassium carbonate  
8 (570.29mg, 4.13 mmol) were added. The reaction was stirred for 15 h. Water was  
9 added and the mixture was extracted with ethyl acetate. Then, the organics were  
10 washed with water (x2) and brine, dried, concentrated, and purified by column  
11 chromatography (1 to 5% MeOH in DCM) to yield 3-((7-chlorothieno[3,2-b]pyridin-2-  
12 yl)methyl)pyrimidin-4(3H)-one (267 mg, 70%). Step 2: The title compound was  
13 synthesized following general procedure A with 3-((7-chlorothieno[3,2-b]pyridin-2-  
14 yl)methyl)pyrimidin-4(3H)-one and stannane **56** followed by general procedure C to give  
15 the desired compound as the HCl salt. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 9.14 (s, 1H),  
16 8.97 (d, *J* = 6.0 Hz, 1H), 8.18 (d, *J* = 6.1 Hz, 1H), 8.06 (d, *J* = 7.0 Hz, 1H), 7.95 (s, 1H),  
17 7.65 (d, *J* = 2.1 Hz, 1H), 7.56 (dd, *J* = 2.2, 1.1 Hz, 1H), 6.67 (d, *J* = 6.9 Hz, 1H), 5.91  
18 (dd, *J* = 9.7, 7.0 Hz, 1H), 5.70 (d, *J* = 0.7 Hz, 2H), 3.95 – 3.10 (m, 10H). [M+H] 508.0.

19  
20  
21 **(*R*)-N-((7-(5-chloro-2-(piperazine-1-carbonyl)-2,3-dihydrobenzofuran-7-yl)thieno[3,2-**  
22 **b]pyridin-2-yl)methyl)acetamide (16).** Step 1: To a mixture of (7-chlorothieno[3,2-  
23 b]pyridin-2-yl)methanol (0.5 g, 2.5 mmol), triphenylphosphine (0.78 g, 1.2 equiv.),  
24 phthalimide (0.44 g, 1.2 equiv) in THF was added diisopropyl azodicarboxylate (0.66  
25 mL, 1.3 equiv.). The reaction was stirred for 2 hr before being concentrated, charged  
26 with DCM (10 mL), and filtered to afford 2-((7-chlorothieno[3,2-b]pyridin-2-  
27 yl)methyl)isoindoline-1,3-dione as an off-white solid (0.47 g, 57% yield) which was used  
28 directly in the following step. Step 2: The above solid (0.47 g, 1.43 mmol) was dissolved  
29 in ethanol (10 mL) and hydrazine (0.4 mL, 5 equiv.) was added. The reaction mixture  
30 was heated to 70 °C for 1 h. The reaction mixture was concentrated in vacuo, diluted  
31 with water (10 mL) and ethyl acetate (25 mL), and the aqueous layer was back-  
32 extracted with ethyl acetate (25 mL). The combined organic layers were washed with  
33 brine, dried over sodium sulfate, filtered, and concentrated to afford (7-chlorothieno[3,2-  
34 b]pyridin-2-yl)methanamine (0.28 g, 99% yield) which was used directly in the following  
35 step. Step 3: The above material (0.28 g, 1.41 mmol) was dissolved in THF (5 mL), then  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 triethylamine (0.3 mL, 1.5 equiv.), acetic anhydride (0.036 mL, 2.2 equiv.), and pyridine  
5 (110 mg, 1.0 equiv.) were added. The solution was allowed to stir overnight. The  
6 solution was concentrated in vacuo, diluted with water (10 mL), and extracted with ethyl  
7 acetate (2 x 10 mL). The combined organic layers were washed with brine, dried,  
8 filtered, and concentrated to afford a residue which was purified by flash column  
9 chromatography (silica gel, 100% ethyl acetate) to afford N-((7-chlorothieno[3,2-  
10 b]pyridin-2-yl)methyl)acetamide (0.19 g, 56% yield). Step 4: The title compound was  
11 synthesized following general procedure A with N-((7-chlorothieno[3,2-b]pyridin-2-  
12 yl)methyl)acetamide and stannane **56** followed by general procedure C to give the  
13 desired compound as the HCl salt. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm 8.93 (bs,  
14 1H), 8.12 (s, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.54 (s, 1H), 5.90 (bs, 1H), 4.80 (s, 2H),  
15 3.95-3.12 (m, 10H), 2.04 (s, 3H). [M+H] 471.0.

16  
17  
18  
19  
20  
21  
22  
23  
24  
25 **(R)-1-((7-(5-chloro-2-(piperazine-1-carbonyl)-2,3-dihydrobenzofuran-7-yl)thieno[3,2-**  
26 **b]pyridin-2-yl)methyl)pyrrolidin-2-one (17)**. Step 1: To 2-pyrrolidone (117 mg, 1.38  
27 mmol, 2.0 equiv.) in DMF (2.3 mL) was added sodium hydride (41 mg, 1.03 mmol, 60%  
28 dispersion in mineral oil). After 20 min, 7-chloro-2-(chloromethyl)thieno[3,2-b]pyridine  
29 was added in one portion. After 30 min, the reaction mixture was quenched with sat. aq.  
30 ammonium chloride (10 mL) and extracted with ethyl acetate (2 x 10 mL). The organic  
31 layers were concentrated and the residue purified by flash column chromatography  
32 (100% EA, then 0-10% MeOH in DCM) to afford 1-[(7-chlorothieno[3,2-b]pyridine-2-  
33 yl)methyl]pyrrolidine-2-one as a thick oil (35 mg, 19% yield). Step 2: The title compound  
34 was synthesized following general procedure A with 1-[(7-chlorothieno[3,2-b]pyridine-2-  
35 yl)methyl]pyrrolidine-2-one and stannane **56** followed by general procedures D and E to  
36 give the desired compound as the free base. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm  
37 8.63 (bs, 1H), 7.54 (s, 1H), 7.45 (s, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 5.74 (dd, J=9.6,  
38 6.8Hz, 1H), 4.59 (s, 2H), 3.74-3.39 (m, 10H), 2.43 (t, J=8.0Hz, 2H), 2.09 (quin, J=7.2Hz,  
39 2H). [M+H] 497.0.

40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 **(R)-1-((7-(5-chloro-2-(piperazine-1-carbonyl)-2,3-dihydrobenzofuran-7-yl)thieno[3,2-**  
52 **b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (18)**. The title compound was synthesized  
53 following general procedure A using stannane **56** (100 mg, 0.156 mmol) and 1-((7-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 chlorothieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**45**) followed by general  
5 procedures D and E to afford the desired compound as the free base (15 mg, 0.026  
6 mmol, 17% yield). <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>): δ ppm 8.93 (bs, 1H), 8.08 (bs, 1H),  
7 7.78 (s, 1H), 7.64 (s, 1H), 7.57 (s, 1H), 5.93 (m, 1H), 5.14 (s, 2H), 3.99-3.10 (m, 10H),  
8 2.84 (s, 4H). [M+H] 511.0.

9  
10  
11  
12 **(R)**-1-((7-(2-(4-(azetidin-1-ylmethyl)oxazol-5-yl)-5-chloro-2,3-dihydrobenzofuran-7-  
13 yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**19**). Step 1: To a solution of  
14 (2*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (**53**, 1.0 g, 3.6 mmol) in  
15 DMF (5.5 mL) was added potassium carbonate (2.0 g, 14.4 mmol), diphenylphosphoryl  
16 azide (1.01 mL, 4.7 mmol), and ethyl isocyanoacetate (0.79 mL, 7.2 mmol). After stirring  
17 for 15 hours, the reaction was diluted with water (50 mL) and brine (50 mL) and  
18 extracted with EtOAc (2 x 50 mL). The organics were dried, concentrated, and purified  
19 by column chromatography (20-100% EtOAc/hexane) to yield ethyl 5-[(2*R*)-7-bromo-5-  
20 chloro-2,3-dihydrobenzofuran-2-yl]oxazole-4-carboxylate (389 mg, 29%). Step 2: To a  
21 solution of ethyl 5-[(2*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl]oxazole-4-  
22 carboxylate (190 mg, 0.53 mmol) in THF (4.5 mL) was added water (0.5 mL) and sodium  
23 borohydride (100 mg, 2.65 mmol). After stirring vigorously for 3 days, the reaction was  
24 diluted with water and extracted with EtOAc (2 x 5 mL). The organics were dried,  
25 concentrated, and purified by column chromatography (0-100% EtOAc/hexane) to yield  
26 [5-[(2*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl]oxazol-4-yl]methanol (77 mg,  
27 44%). Step 3: [5-[(2*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl]oxazol-4-  
28 yl]methanol (60 mg, 0.18 mmol) and 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
29 yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**, 81 mg, 0.22 mmol) were  
30 utilized with general procedure B to afford 1-[[7-[(2*R*)-5-chloro-2-[4-  
31 (hydroxymethyl)oxazol-5-yl]-2,3-dihydrobenzofuran-7-yl]thieno[3,2-b]pyridin-2-  
32 yl]methyl]pyrrolidine-2,5-dione (7.5 mg, 8%). Step 4: To a solution of 1-[[7-[(2*R*)-5-  
33 chloro-2-[4-(hydroxymethyl)oxazol-5-yl]-2,3-dihydrobenzofuran-7-yl]thieno[3,2-b]pyridin-  
34 2-yl]methyl]pyrrolidine-2,5-dione (7.5 mg, 0.015 mmol) in DCM (0.3 mL) was added  
35 sodium bicarbonate (2.5 mg, 0.03 mmol) and Dess-Martin periodinane (7.4 mg, 0.017  
36 mmol). This solution was stirred for 1 hour, then filtered through Celite and  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 concentrated, then purified by column chromatography (0-100% EtOAc/hexane) to yield  
5 (*R*)-5-(5-chloro-7-(2-((2,5-dioxopyrrolidin-1-yl)methyl)thieno[3,2-*b*]pyridin-7-yl)-2,3-  
6 dihydrobenzofuran-2-yl)oxazole-4-carbaldehyde (3 mg, 40%). Step 5: To a solution of  
7 (*R*)-5-(5-chloro-7-(2-((2,5-dioxopyrrolidin-1-yl)methyl)thieno[3,2-*b*]pyridin-7-yl)-2,3-  
8 dihydrobenzofuran-2-yl)oxazole-4-carbaldehyde (3 mg, 0.006 mmol) in DCE (0.3 mL)  
9 was added azetidine HCl (2.9 mg, 0.03 mmol) and sodium triacetoxyborohydride (2.6  
10 mg, 0.01 mmol). After stirring for 2 hours, the reaction was quenched with 1 M NaOH (1  
11 mL) and extracted with DCM (3 x 1 mL). The organics were dried and concentrated and  
12 purified by column chromatography (1-10% MeOH/DCM) to give the desired product as  
13 the free base. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 8.78 (d, *J* = 4.9 Hz, 1H), 8.32 (s, 1H),  
14 7.65 (s, 1H), 7.62 (d, *J* = 2.4 Hz, 1H), 7.60 (d, *J* = 2.2 Hz, 1H), 7.58 (d, *J* = 4.9 Hz, 1H),  
15 6.33 (dd, *J* = 9.8, 7.4 Hz, 1H), 5.10 (s, 2H), 3.91 (dd, *J* = 16.3, 9.9 Hz, 1H), 3.76 (dd, *J* =  
16 16.3, 7.4 Hz, 1H), 3.68 (d, *J* = 8.1 Hz, 2H), 3.40 – 3.30 (m, 4H), 2.93 (s, 4H), 2.15 (p, *J* =  
17 7.1 Hz, 2H). [M+H] 535.0.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**(*R*)-1-((7-(5-chloro-2-(4,5,6,7-tetrahydroisoxazolo[4,3-*c*]pyridin-3-yl)-2,3-  
dihydrobenzofuran-7-yl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (20).** Step  
1: To a stirred solution of (*2R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carboxylic  
acid (**53**, 9.37 g, 33.8 mmol) in DCM (68 mL) at 0 °C was added DMF (2 drops),  
followed by oxalyl chloride (5.8 mL, 2.0 equiv.) dropwise over 3 min. The solution was  
allowed to warm to room temperature over 20 min and concentrated in vacuo to give the  
acid chloride (10 g). In a separate flask, a solution of tert-butyl 4-oxopiperidine-1-  
carboxylate (10.8 g, 54.2 mmol, 1.6 equiv.) in anhydrous THF (125 mL) at –78 °C was  
added a solution of LiHMDS (54.2 mL, 1 M in THF, 54.2 mmol, 1.6 equiv.). The solution  
was stirred at –78 °C for 50 min before the addition of a solution of the above acid  
chloride (10.0 g, 33.9 mmol) in THF (5 mL). The resulting mixture was stirred at –78 °C  
for 1 hr, then warmed to 0 °C. The reaction was quenched with half sat. aq. NH<sub>4</sub>Cl at 0  
°C and the aqueous layer was extracted with ethyl acetate (2 x 200 mL). The combined  
organic layers were concentrated and the crude product was purified by column  
chromatography (5-25% EtOAc/hexanes) to afford tert-butyl 3-((*R*)-7-bromo-5-chloro-  
2,3-dihydrobenzofuran-2-carbonyl)-4-oxopiperidine-1-carboxylate (6.8 g, 44%). Step 2:

To a solution of tert-butyl 3-((*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-carbonyl)-4-oxopiperidine-1-carboxylate (3.3 g, 7.2 mmol) in EtOH (30 mL) was added NH<sub>2</sub>OH·HCl (746 mg, 10.8 mmol, 1.5 equiv.), followed by NaOAc·3H<sub>2</sub>O (2.94 g, 21.6 mmol, 3.0 equiv.). The mixture was heated to 82 °C for 2 hr, then cooled to room temperature and concentrated in vacuo. The residue was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with sat. aq. NaHCO<sub>3</sub>, dried over sodium sulfate, filtered, and concentrated to give the oxime (3.4 g). To this oxime (3.4 g, 7.2 mmol) in DCM (40 mL) was added MsCl (1.81 g, 15.9 mmol) and triethylamine (4.38 mL, 31.0 mmol). The mixture was stirred at room temperature for 2 hr and concentrated in vacuo. The residue was extracted with ethyl acetate (200 mL) and the organic layer was washed with 1M aq. HCl (100 mL), water (100 mL), and brine (100 mL). The organic layer was concentrated and the residue was purified by column chromatography (5-30% EtOAc/hexanes) to afford tert-butyl (*R*)-3-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate (1.8 g, 55%). Step 3: To tert-butyl (*R*)-3-(7-bromo-5-chloro-2,3-dihydrobenzofuran-2-yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate (6.0 g, 13.2 mmol), bis(pinacolato)diboron (4.18 g, 16.5 mmol, 1.25 equiv.), potassium acetate (1.62 g, 16.5 mmol, 1.25 equiv.), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (530 mg, 0.72 mmol, 0.06 equiv.) was added 1,4-dioxane (60 mL) in a 150 mL sealed tube. The vessel was heated to 100 °C for 6 hr, then cooled to room temperature, diluted with ethyl acetate (100 mL), and filtered through a pad of celite, washing with ethyl acetate. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography (0-100% EtOAc/hexanes) to afford tert-butyl (*R*)-3-(5-chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-2-yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate as a brown foam (5.35 g, 81% yield). Step 4: To a mixture of 1-((7-chlorothieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**45**, 109 mg, 0.39 mmol), tert-butyl (*R*)-3-(5-chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-2-yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate (390 mg, 0.78 mmol, 2.0 equiv.), Xphos (18.5 mg, 0.04 mmol, 0.1 equiv.), Pd(OAc)<sub>2</sub> (8.7 mg, 0.04 mmol, 0.1 equiv.), and K<sub>3</sub>PO<sub>4</sub> (247 mg, 1.16 mmol, 3.0 equiv.) was added THF (1.1 mL) and water (0.2 mL). The mixture was

1  
2  
3  
4 sparged with Ar for 5 min and heated to 60 °C with stirring for 5 h in a sealed vial. The  
5 mixture was cooled to room temperature and diluted with water (10 mL) and ethyl  
6 acetate (10 mL). The organic layer was concentrated and purified by flash column  
7 chromatography (50-100% ethyl acetate/hexanes) to afford tert-butyl (*R*)-3-(5-chloro-7-  
8 (2-((2,5-dioxopyrrolidin-1-yl)methyl)thieno[3,2-*b*]pyridin-7-yl)-2,3-dihydrobenzofuran-2-  
9 yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate (49 mg, 20% yield). Step 5:  
10 The title compound was synthesized following general procedure C with tert-butyl (*R*)-3-  
11 (5-chloro-7-(2-((2,5-dioxopyrrolidin-1-yl)methyl)thieno[3,2-*b*]pyridin-7-yl)-2,3-  
12 dihydrobenzofuran-2-yl)-6,7-dihydroisoxazolo[4,3-*c*]pyridine-5(4H)-carboxylate (49 mg,  
13 0.08 mmol) to give the desired compound as the HCl salt (44 mg, 99% yield). <sup>1</sup>H NMR  
14 (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.89 (s, 1H), 7.93 (s, 1H), 7.73 (s, 1H), 7.61 (s, 2H), 6.22 (s,  
15 1H), 5.04 (s, 2H), 4.28 – 4.12 (m, 1H), 3.89 – 3.43 (m, 5H), 3.18 – 3.08 (m, 2H), 2.77 (s,  
16 4H). [M+H] 521.0.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 **(*R*)-1-((7-(5-chloro-2-(2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,3-  
28 dihydrobenzofuran-7-yl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (21).** Step  
29 1: To a solution of tert-butyl 3-((*R*)-7-bromo-5-chloro-2,3-dihydrobenzofuran-2-  
30 carbonyl)-4-oxopiperidine-1-carboxylate (5 g, 10.9 mmol) in ethanol (50 mL) was added  
31 anhydrous hydrazine (1.4 g, 43.7 mmol, 4 equiv). The mixture was heated to 62 °C for  
32 1.5 h with stirring. The mixture was cooled, concentrated and partitioned between  
33 EtOAc and H<sub>2</sub>O. The organic layer is washed with sat. aq. NaHCO<sub>3</sub>, concentrated and  
34 dried over sodium sulfate to afford tert-butyl (*R*)-3-(7-bromo-5-chloro-2,3-  
35 dihydrobenzofuran-2-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridine-5-carboxylate as  
36 a white solid (4.9 g, 98%). [M+H] = 454. Step 2: To a stirred suspension of (*R*)-3-(7-  
37 bromo-5-chloro-2,3-dihydrobenzofuran-2-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-  
38 *c*]pyridine-5-carboxylate (1.6 g, 3.5 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.46 g, 10.6 mmol, 3.0  
39 equiv) in DMF (10 mL) was added methyl iodide (548 μL, 8.8 mmol, 2.5 equiv). The  
40 resulting suspension was stirred overnight. The mixture was quenched with water and  
41 extracted w/ EtOAc (3 x 50 mL). The combined organic layers were washed with water  
42 (100 mL) and concentrated in vacuo. The crude mixture was purified by flash column  
43 chromatography (0-40% EtOAc in hexanes) to afford tert-butyl (*R*)-3-(7-bromo-5-chloro-  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 2,3-dihydrobenzofuran-2-yl)-2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-  
5 carboxylate (958 mg, 58% yield). [M+H] 468. Step 3: The title compound was  
6 synthesized following general procedure B with tert-butyl (*R*)-3-(7-bromo-5-chloro-2,3-  
7 dihydrobenzofuran-2-yl)-2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-  
8 carboxylate and pyridine boronic ester **46** followed by general procedure C to give the  
9 desired product as the HCl salt. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.60 (d, *J* = 4.9 Hz,  
10 1H), 7.46 (t, *J* = 0.8 Hz, 1H), 7.43 – 7.39 (m, 3H), 5.90 (dd, *J* = 9.4, 8.0 Hz, 1H), 4.93 (d,  
11 *J* = 0.9 Hz, 2H), 3.91 (q, *J* = 15.8, 14.7, 14.7 Hz, 2H), 3.73 (s, 3H), 3.70 – 3.55 (m, 2H),  
12 3.43 – 3.34 (m, 2H), 2.90 (t, *J* = 6.1 Hz, 2H), 2.74 (s, 4H). [M+H] 534.0.

13  
14  
15  
16  
17  
18  
19  
20 **General Procedure F (Mitsunobu Reaction).** Diisopropyl azodicarboxylate (0.3 mL, 1.5  
21 mmol) was added to a stirring mixture of 2-bromo-4-chloro-6-methylphenol (**60**, 0.22 g,  
22 1.0 mmol), triphenylphosphine (0.39 g, 1.5 mmol), and an appropriate substituted  
23 alcohol (**61**, 1.2 mmol) in THF (3 mL) and stirred overnight. The reaction mixture was  
24 concentrated and purified by column chromatography (0-30% EtOAc in hexane) to give  
25 the desired product (**62**).  
26  
27  
28  
29

30  
31 **1-((7-(5-Chloro-2-(((3*R*,4*S*)-4-fluoropyrrolidin-3-yl)oxy)phenyl)thieno[3,2-*b*]pyridin-2-  
32 yl)methyl)pyrrolidine-2,5-dione (**22**).** The title compound was synthesized following  
33 general procedure F using 2-bromo-4-chlorophenol and tert-butyl (3*S*,4*S*)-3-fluoro-4-  
34 hydroxypyrrolidine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-  
35 tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-  
36 dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz,  
37 Methanol-*d*<sub>4</sub>) δ 8.66 (m, 1H), 7.53 (m, 3H), 7.45 (m, 1H), 7.32 (m, 1H), 5.46 (m, 1H),  
38 5.19 (m, 1H), 4.96 (s, 2H), 3.69 (m, 1H), 3.59 (m, 2H), 3.16 (m, 2H), 2.71 (s, 4H). [M+H]  
39 462.0.  
40  
41  
42  
43  
44  
45

46  
47 **1-((4-(5-Chloro-2-(((3*R*,4*S*)-4-fluoropyrrolidin-3-yl)oxy)-3-methylphenyl)thieno[3,2-  
48 d]pyrimidin-6-yl)methyl)pyrrolidine-2,5-dione (**23**).** The title compound was synthesized  
49 following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and tert-  
50 butyl (3*S*,4*S*)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate, followed by general  
51 procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-*b*]pyridin-  
52 2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired  
53  
54  
55  
56  
57  
58  
59  
60

product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.68 (d, J = 4.9 Hz, 1H), 7.88 – 7.64 (m, 2H), 7.51 – 7.26 (m, 2H), 5.02 – 4.93 (m, 1H), 4.73 – 4.38 (m, 1H), 4.06 – 3.79 (m, 1H), 3.30 (s, 4H), 2.99 – 2.74 (m, 2H), 2.64 – 2.52 (m, 1H), 2.47 (s, 3H), 2.44 – 2.26 (m, 1H), 2.01 – 1.81 (m, 2H). [M+H] 474.1.

**(S)-1-((7-(5-Chloro-3-methyl-2-(piperidin-3-yloxy)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (24).** The title compound was synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and tert-butyl (R)-3-hydroxypiperidine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**) then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.80 (d, J = 5.3 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.50 (dd, J = 2.7, 0.8 Hz, 1H), 7.41 (dd, J = 2.6, 0.6 Hz, 1H), 5.01 (d, J = 0.9 Hz, 2H), 3.81 – 3.70 (m, 1H), 3.06 – 2.94 (m, 2H), 2.94 – 2.85 (m, 1H), 2.83 – 2.71 (m, 5H), 2.43 (d, J = 0.7 Hz, 3H), 1.61 (tt, J = 17.2, 9.2 Hz, 2H), 1.44 – 1.24 (m, 2H). [M+H] 470.0.

**1-((7-(5-Chloro-3-methyl-2-(piperidin-4-yloxy)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (25).** The title compound was synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and tert-butyl 4-hydroxypiperidine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.77 (d, J = 5.2 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.49 (dq, J = 2.8, 0.7 Hz, 1H), 7.38 (dd, J = 2.7, 0.7 Hz, 1H), 5.00 (d, J = 1.0 Hz, 2H), 3.93 – 3.83 (m, 1H), 2.93 – 2.78 (m, 3H), 2.76 (s, 4H), 2.42 (d, J = 0.7 Hz, 3H), 1.83 – 1.68 (m, 2H), 1.58 – 1.44 (m, 2H). [M+H] 470.0.

**1-((7-(5-Chloro-2-((3-fluoroazetidin-3-yl)methoxy)-3-methylphenyl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (26).** The title compound was synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and tert-butyl 3-fluoro-3-(hydroxymethyl)azetidine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400

MHz, MeOH-d<sub>4</sub>) δ 8.66 (m, 1H), 7.51 (m, 1H), 7.42 (m, 2H), 7.34 (m, 1H), 4.96 (m, 2H), 3.70 (s, 2H), 3.47 (m, 2H), 3.21 (m, 2H), 2.75 (s, 4H), 2.39 (s, 3H). [M+H] 475.0.

**1-((7-(2-((1*r*,3*r*)-3-aminocyclobutoxy)-5-chloro-3-methylphenyl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (27).** The title compound was synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and *cis*-*tert*-butyl (3-hydroxycyclobutyl)carbamate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.77 (d, *J* = 5.0 Hz, 1H), 7.60 (s, 1H), 7.57 (dd, *J* = 5.2, 1.0 Hz, 1H), 7.46 (dd, *J* = 2.6, 0.8 Hz, 1H), 7.37 (dd, *J* = 2.7, 0.8 Hz, 1H), 5.00 (s, 2H), 4.32 – 4.23 (m, 1H), 3.52 (dq, *J* = 8.6, 4.3 Hz, 1H), 2.77 (s, 4H), 2.37 (s, 3H), 2.23 – 2.14 (m, 2H), 2.06 – 1.96 (m, 2H). [M+H] 456.0.

**1-((7-(5-Chloro-3-methyl-2-(((3*R*,4*S*)-3-methylpiperidin-4-yl)oxy)phenyl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (28).** The title compound was synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**) and *tert*-butyl (3*R*,4*R*)-4-hydroxy-3-methylpiperidine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-*b*]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.79 (s, 1H), 7.62 – 7.51 (m, 2H), 7.44 (d, *J* = 2.6 Hz, 1H), 7.32 (d, *J* = 2.6 Hz, 1H), 4.97 (s, 2H), 4.12 – 3.98 (m, 1H), 2.88 (dd, *J* = 12.6, 4.0 Hz, 1H), 2.74 (s, 4H), 2.67 – 2.46 (m, 3H), 2.44 (s, 3H), 2.12 – 1.80 (m, 2H), 1.58 – 1.38 (m, 2H), 0.92 (d, *J* = 6.9 Hz, 3H). [M+H] 484.0.

**General Procedure G (Late-Stage Chlorination/Displacement).** Step 1: To a solution of TBS-ether (such as **64** or **80**, 0.2 mmol) in THF (2 mL) was added tetra-*n*-butylammonium fluoride (0.3 mL, 0.3 mmol). This solution was allowed to stir at room temperature for 1 hour. The solution was concentrated and purified by column chromatography (1-4% MeOH/DCM) to give the primary alcohol. Step 2: This primary alcohol (~0.2 mmol) was dissolved in DCM (2 mL) after which *N,N*-diisopropylethylamine (0.11 mL, 0.6 mmol) and methanesulfonyl chloride (0.02 mL, 0.3 mmol) were sequentially added. After stirring at room temperature for 12 hours, the

1  
2  
3  
4 mixture was diluted with DCM (5 mL) and washed with 1 N HCl (1 x 5 mL), sat aq.  
5 NaHCO<sub>3</sub> (1 x 5 mL), and brine (1 x 5 mL). The organics were dried over Na<sub>2</sub>SO<sub>4</sub> and  
6 concentrated to give the benzylic chloride. To this crude material in acetonitrile (2 mL)  
7 was added cesium carbonate (195 mg, 0.6 mmol) and the desired cyclic imide (0.6  
8 mmol) and heated to 60 °C for 3 hours. After cooling, the reaction was quenched with  
9 water along with a small amount of trifluoroacetic acid and purified directly by reverse  
10 phase chromatography to give the desired product.  
11  
12  
13  
14  
15

16 **3-((7-(5-chloro-3-methyl-2-(((3S,4R)-3-methylpiperidin-4-yl)oxy)phenyl)thieno[3,2-**  
17 **b]pyridin-2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione (29)**. The title compound was  
18 synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**)  
19 and tert-butyl (3R,4R)-4-hydroxy-3-methylpiperidine-1-carboxylate, then general  
20 procedure B with 2-(((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-  
21 dioxaborolan-2-yl)thieno[3,2-b]pyridine (**48**), followed by general procedure G with 3-  
22 azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired  
23 product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.76 (d, *J* = 5.1 Hz, 1H), 7.58 – 7.51 (m,  
24 2H), 7.46 (d, *J* = 2.7 Hz, 1H), 7.34 (d, *J* = 2.7 Hz, 1H), 4.83 (s, 2H), 4.09 (s, 1H), 2.89  
25 (dd, *J* = 12.6, 3.9 Hz, 1H), 2.64 (dd, *J* = 11.1, 6.5 Hz, 1H), 2.60 (d, *J* = 3.6 Hz, 1H), 2.58  
26 (d, *J* = 3.6 Hz, 1H), 2.46 (s, 3H), 2.03 – 1.87 (m, 2H), 1.66 – 1.57 (m, 1H), 1.59 – 1.49  
27 (m, 2H), 1.47 – 1.38 (m, 1H), 0.95 (d, *J* = 6.9 Hz, 3H). [M+H] 496.0.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **3-((7-(5-chloro-3-methyl-2-(((3S,4R)-3-methylpiperidin-4-yl)oxy)phenyl)thieno[3,2-**  
39 **b]pyridin-2-yl)methyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione (30)**. The title  
40 compound was synthesized following general procedure F using 2-bromo-4-chloro-6-  
41 methylphenol (**60**) and tert-butyl (3R,4R)-4-hydroxy-3-methylpiperidine-1-carboxylate,  
42 then general procedure B with 2-(((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-  
43 tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridine (**48**), followed by general  
44 procedure G with 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione, then general  
45 procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.76 (d, *J*  
46 = 5.1 Hz, 1H), 7.57 (s, 1H), 7.53 (d, *J* = 5.0 Hz, 1H), 7.46 (d, *J* = 2.7 Hz, 1H), 7.34 (d, *J*  
47 = 2.7 Hz, 1H), 4.88 (s, 2H), 4.08 (s, 1H), 2.90 (dd, *J* = 12.7, 4.0 Hz, 1H), 2.68 – 2.52 (m,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 1H), 2.50 (s, 2H), 2.53 – 2.41 (m, 1H), 2.46 (s, 3H), 2.08 – 1.85 (m, 2H), 1.62 – 1.43 (m,  
5 2H), 1.24 (s, 3H), 1.11 (s, 3H), 0.94 (d,  $J = 7.0$  Hz, 3H). [M+H] 524.0.

6  
7  
8 **3-((7-(5-Chloro-3-methyl-2-(((3S,4R)-3-methylpiperidin-4-yl)oxy)phenyl)thieno[3,2-**  
9 **b]pyridin-2-yl)methyl)-1-(2,2,2-trifluoroethyl)pyrimidine-2,4(1H,3H)-dione (31).** The title  
10 compound was synthesized following general procedure F using 2-bromo-4-chloro-6-  
11 methylphenol (**60**) and tert-butyl (3R,4R)-4-hydroxy-3-methylpiperidine-1-carboxylate,  
12 then general procedure B with 2-(((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-  
13 tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridine (**48**), followed by general  
14 procedure G with 1-(2,2,2-trifluoroethyl)pyrimidine-2,4(1H,3H)-dione, then general  
15 procedure D to give the desired product as the TFA salt.  $^1\text{H}$  NMR (400 MHz, Methanol-  
16  $d_4$ )  $\delta$  8.77 (d,  $J = 5.1$  Hz, 1H), 7.70 – 7.60 (m, 2H), 7.55 (d,  $J = 5.1$  Hz, 1H), 7.46 (d,  $J =$   
17 2.6 Hz, 1H), 7.34 (d,  $J = 2.7$  Hz, 1H), 5.88 (d,  $J = 8.0$  Hz, 1H), 5.43 (s, 2H), 4.71 – 4.47  
18 (m, 2H), 4.02 (s, 1H), 2.91 – 2.75 (m, 1H), 2.73 – 2.58 (m, 1H), 2.45 (s, 3H), 2.47 – 2.36  
19 (m, 1H), 2.10 – 1.81 (m, 2H), 1.63 – 1.36 (m, 2H), 0.89 (d,  $J = 6.7$  Hz, 3H). [M+H]  
20 579.0.

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 **3-((7-(5-chloro-3-methyl-2-(piperidin-3-yloxy)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-**  
32 **6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione (32).** The title compound was  
33 synthesized following general procedure F using 2-bromo-4-chloro-6-methylphenol (**60**)  
34 and tert-butyl 3-hydroxypiperidine-1-carboxylate, then general procedure B with 2-  
35 (((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
36 yl)thieno[3,2-b]pyridine (**48**), followed by general procedure G with 6,6-dimethyl-3-  
37 azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired  
38 product. [M+H] 510.0.

39  
40  
41  
42  
43  
44  
45 **3-((7-(5-chloro-3-methyl-2-(piperidin-3-ylamino)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-**  
46 **6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione (33).** Step 1: Sodium  
47 triacetoxyborohydride (12.96 g, 61.1 mmol) was added to a solution of 2-bromo-4-  
48 chloro-6-methylaniline (3.37 g, 15.3 mmol) and 1-Boc-3-piperidone (9.14 g, 34.0 mmol)  
49 and acetic acid (7 mL, 122 mmol) in DCM (20 mL) and the reaction mixture was stirred  
50 at 60 °C overnight. The reaction was quenched with 1N NaOH (20 mL) and extracted  
51 with EtOAc (3 x 60 mL). The combined organic layers were washed with brine (60 mL),  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 concentrated, and purified by column chromatography (0-100% EtOAc in hexanes) to  
5 give tert-butyl 3-((2-bromo-4-chloro-6-methylphenyl)amino)piperidine-1-carboxylate as a  
6 light brown viscous oil (2.1 g). Step 2: The title compound was synthesized following  
7 general procedure B with tert-butyl 3-((2-bromo-4-chloro-6-  
8 methylphenyl)amino)piperidine-1-carboxylate and 2-(((tert-  
9 butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-  
10 b]pyridine (**48**), followed by general procedure G with 6,6-dimethyl-3-  
11 azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired  
12 product as the TFA salt. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.64 (d, *J* = 4.9 Hz, 1H),  
13 7.47 (s, 1H), 7.41 (d, *J* = 4.9 Hz, 1H), 7.26 (d, *J* = 2.6 Hz, 1H), 7.08 (d, *J* = 2.6 Hz, 1H),  
14 5.48 (s, 2H), 2.67 – 2.55 (m, 2H), 2.47 (s, 2H), 2.43 – 2.30 (m, 2H), 2.33 (s, 3H), 2.13  
15 (dd, *J* = 12.0, 9.3 Hz, 1H), 1.48 – 1.40 (m, 2H), 1.21 (s, 3H), 1.06 (s, 3H), 1.04 – 0.97  
16 (m, 2H). [M+H] 509.0.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 **3-((7-(5-chloro-3-methyl-2-(piperidin-3-ylmethyl)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-**  
28 **6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione (34)**. Step 1: A solution of Boc-4-  
29 piperidone (3.0 g, 15 mmol) and 1-phenylethylamine (1.82 g, 15 mmol) in toluene (75  
30 mL) was heated to reflux under a Dean Stark apparatus for 12 hours. After cooling, the  
31 reaction mixture was concentrated to yield tert-butyl 4-((1-phenylethyl)imino)piperidine-  
32 1-carboxylate (4.5 g, 99%). Step 2: A solution of tert-butyl 4-(1-  
33 phenylethylimino)piperidine-1-carboxylate (2.0 g, 6.6 mmol) in THF (33 mL) was cooled  
34 to -78 °C, then lithium diisopropylamide (2 M, 3.0 mL, 6.0 mmol) was added dropwise.  
35 After stirring for 30 minutes at -78 °C, a solution of 1-bromo-2-(bromomethyl)-5-chloro-  
36 3-methylbenzene (2.0 g, 6.6 mmol) in THF (10 mL) was added dropwise. After stirring  
37 for 20 minutes at -78 °C, the reaction mixture was allowed to slowly warm to room  
38 temperature over the course of 1 hour. The reaction was quenched with NH<sub>4</sub>Cl (20 mL),  
39 extracted with EtOAc, and concentrated. This crude material was dissolved in methanol  
40 (10 mL), after which 1 M HCl (10 mL) was added. This mixture was stirred at room  
41 temperature overnight. Partial Boc cleavage was also observed, so re-subjection to  
42 standard Boc protection conditions can be employed. The product was purified by  
43 column chromatography (0-30% EtOAc in hexane) to yield tert-butyl 3-(2-bromo-4-  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 chloro-6-methylbenzyl)-4-oxopiperidine-1-carboxylate (0.9 g, 62%). Step 3: A solution of  
5 tert-butyl 3-(2-bromo-4-chloro-6-methylbenzyl)-4-oxopiperidine-1-carboxylate (200 mg,  
6 0.48 mmol) and 4-methylbenzenesulfonylhydrazide (107 mg, 0.58 mmol) in ethanol (2.4  
7 mL) was heated to reflux for 6 hours. After cooling, the reaction mixture was  
8 concentrated. This crude material was dissolved in THF (2.4 mL) and cooled to 0 °C.  
9 Sodium borohydride (280 mg, 7.5 mmol) was added slowly, then the reaction was  
10 heated to reflux for 15 hours. After cooling, water (5 mL) was added and extracted with  
11 EtOAc (3 x 5 mL). The combined organic layers were dried over sodium sulfate, filtered,  
12 concentrated, and purified by column chromatography (0-50% EtOAc/hexane) to yield  
13 tert-butyl 3-(2-bromo-4-chloro-6-methylbenzyl)piperidine-1-carboxylate (130 mg, 64%).  
14 Step 4: The title compound was synthesized following general procedure B with tert-  
15 butyl 3-(2-bromo-4-chloro-6-methylbenzyl)piperidine-1-carboxylate and 2-(((tert-  
16 butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-  
17 b]pyridine (**48**), followed by general procedure G with 6,6-dimethyl-3-  
18 azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired  
19 product as the TFA salt. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.75 (d, *J* = 5.0 Hz, 1H),  
20 7.58 (s, 1H), 7.48 – 7.38 (m, 2H), 7.18 (d, *J* = 6.6 Hz, 1H), 4.85 (s, 2H), 3.18 (d, *J* = 12.6  
21 Hz, 1H), 3.00 (dd, *J* = 22.6, 12.5 Hz, 1H), 2.81 – 2.59 (m, 2H), 2.50 (d, *J* = 2.7 Hz, 2H),  
22 2.47 (s, 3H), 2.43 – 2.28 (m, 2H), 1.81 – 1.54 (m, 2H), 1.54 – 1.27 (m, 2H), 1.24 (s, 3H),  
23 1.09 (d, *J* = 6.7 Hz, 3H), 0.98 – 0.79 (m, 1H). [M+H] 508.0.

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 **2-(bromomethyl)-5-chloro-1-iodo-3-methylbenzene (67)**: Step 1: 4-Chloro-2-  
40 methylbenzoic acid (100 g, 586 mmol) and NIS (158 g, 703 mmol) were dissolved in  
41 DMF (1 L, 0.6M) at which time Pd(OAc)<sub>2</sub> (13.2 g, 58.6 mmol) was added. The mixture  
42 was heated to 120 °C for 16 h, cooled, concentrated. The mixture was partitioned  
43 between EtOAc and water, and the organic phase washed with brine, dried over  
44 Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude mixture was purified by silica gel  
45 chromatography to yield 4-chloro-2-iodo-6-methylbenzoic acid (51 g, 172 mmol, 30%).  
46 Step 2: The above material was dissolved in THF (325 mL), cooled to 0 °C, and added  
47 borane DMS (34.4 mL, 344 mmol). The mixture was heated to 50 °C and stirred for 20  
48 h. Upon completion, the mixture was cooled to 0 °C then quenched carefully with  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 MeOH. The mixture was concentrated, and water was added to precipitate the product.  
5  
6 The solid was purified by silica gel chromatography to furnish (4-chloro-2-iodo-6-  
7 methylphenyl)methanol (35.3 g, 125 mmol, 73%). Step 3: The above material was  
8 dissolved in DCM (410 mL), cooled to 0 °C, and added PBr<sub>3</sub> (23.6 mL, 250 mmol). The  
9 mixture was allowed to warm to room temperature and stirred 3 h. The mixture was  
10 cooled to 0 °C then quenched with sat. NaHCO<sub>3</sub>. The layers were separated, and the  
11 aqueous layer extracted with DCM (3 x 200 mL). The combined organic layers were  
12 washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the title compound  
13 (38 g, 88%). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 7.71 (d, *J* = 2.1 Hz, 1H), 7.17 (d, *J* =  
14 2.1 Hz, 1H), 4.65 (s, 2H), 2.47 (s, 3H).  
15  
16  
17  
18  
19  
20

21 **General Procedure H (Piperazine Substitution).** To desired mono-Boc-protected  
22 piperazine (**68**, 2.0 mmol) in DMF (5 mL) was added sodium hydride (0.16 g, 4.0 mmol).  
23 The mixture was stirred for 5 min at which time 2-(bromomethyl)-5-chloro-1-iodo-3-  
24 methylbenzene (**67**, 0.83 g, 2.4 mmol) was added. The mixture was stirred for 35 min  
25 and partitioned between sat. NH<sub>4</sub>Cl (2 mL), H<sub>2</sub>O (3 mL), and 50% EtOAc/Hexane (15  
26 mL). The organic layer was separated, concentrated and purified by silica gel  
27 chromatography (0-40% EtOAc in hexane) to afford the desired product (**69**).  
28  
29  
30  
31  
32  
33

34 **1-((7-(5-chloro-3-methyl-2-(piperazin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-2-  
35 yl)methyl)pyrrolidine-2,5-dione (35).** The title compound was synthesized following  
36 general procedure H with 2-(bromomethyl)-5-chloro-1-iodo-3-methylbenzene (**67**) and  
37 tert-butyl piperazine-1-carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-  
38 tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-  
39 dione (**46**), then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz,  
40 Methanol-*d*<sub>4</sub>) δ 8.99 (bs, 1H), 7.97 (s, 1H), 7.85 (s, 1H), 7.59 (s, 1H), 7.39 (s, 1H), 5.08  
41 (s, 2H), 4.15 (bs, 1H), 3.71 (bs, 1H), 3.02 (bs, 4H), 2.78 (s, 4H), 2.68 (bs, 4H), 2.60 (s,  
42 3H). [M+H] 469.0.  
43  
44  
45  
46  
47  
48  
49

50 **(S)-1-((7-(5-chloro-3-methyl-2-((2-methylpiperazin-1-yl)methyl)phenyl)thieno[3,2-  
51 b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (36).** The title compound was synthesized  
52 following general procedure H with 2-(bromomethyl)-5-chloro-1-iodo-3-methylbenzene  
53 (**67**) and tert-butyl (S)-3-methylpiperazine-1-carboxylate, followed by general procedure  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then general procedure D to give the desired  
5 product. <sup>1</sup>H NMR (400 MHz, Methanol-d<sub>4</sub>) δ 8.87 (bs, 1H), 7.70 (s, 1H), 7.66 (s, 1H),  
6 7.47 (s, 1H), 7.27 (s, 1H), 5.03 (s, 2H), 4.29-4.08 (m, 4H), 3.11-2.91 (m, 2H), 2.77 (s,  
7 4H), 2.64-2.56 (m, 1H), 2.52 (s, 3H), 2.45-1.99 (m, 3H), 1.27 (d, J = 7.2 Hz, 3H). [M+H]  
8 483.0.

9  
10  
11  
12  
13  
14 **1-((7-(5-chloro-2-(((2S,6S)-2,6-dimethylpiperazin-1-yl)methyl)-3-**  
15 **methylphenyl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (37).** The title  
16 compound was synthesized following general procedure H with 2-(bromomethyl)-5-  
17 chloro-1-iodo-3-methylbenzene (**67**) and tert-butyl (3S,5S)-3,5-dimethylpiperazine-1-  
18 carboxylate, followed by general procedure B with 1-((7-(4,4,5,5-tetramethyl-1,3,2-  
19 dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)pyrrolidine-2,5-dione (**46**), then  
20 general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-d<sub>4</sub>) δ  
21 9.00 (s, 1H), 8.02 (s, 1H), 7.93 (s, 1H), 7.55 (s, 1H), 7.38 (s, 1H), 5.07 (s, 2H), 4.33-3.95  
22 (m, 2H), 3.15-2.54 (m, 4H), 2.79 (s, 3H), 2.68 (d, J = 11.0 Hz, 4H), 0.93 (bs, 3H), 0.84  
23 (bs, 3H). [M+H] 497.1.

24  
25  
26  
27  
28  
29  
30  
31  
32 **General Procedure I (Morpholine Synthesis).** Step 1: To diisopropylamine (0.31 mL, 2.2  
33 mmol) in THF (10 mL) at 0 °C was added n-butyllithium (2.5 M in hexane, 0.88 mL, 2.2  
34 mmol) dropwise and the solution was stirred at 0 °C for 45 min. The mixture was cooled  
35 to -78 °C at which time substituted PMB-morpholinone (**71**, 2.0 mmol) in THF (5 mL)  
36 was added dropwise. After stirring at -78 °C for 1 h, 2-(bromomethyl)-5-chloro-1-iodo-3-  
37 methylbenzene (**67**, 1.04 g, 3.0 mmol) in THF (5 mL) was added dropwise. The mixture  
38 was allowed to warm to rt and stirred 16 h. To this was added sat. aq. NH<sub>4</sub>Cl (20 mL),  
39 extracted with EtOAc (2 x 20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Silica gel  
40 chromatography afforded the alkylated morpholinone. Step 2: To the above alkylated  
41 morpholinone (1.58 mmol) in THF (3 mL) was added borane tetrahydrofuran (2.0 M in  
42 THF, 2.37 mL, 4.73 mmol) dropwise. The mixture was stirred at 70 °C overnight, then  
43 cooled to 0 °C and quenched carefully with 1:1 THF/H<sub>2</sub>O (10 mL). Sat. aq. Rochelle's  
44 salt (10 mL) was added and the mixture vigorously stirred at rt. The mixture was  
45 extracted with EtOAc (2 x 20 mL) and purified by silica gel chromatography to furnish  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 the desired morpholine (**72**). Step 3: To the above morpholine (**72**, 1.39 mmol) in DCE  
5 (13 mL) was added chloroethyl chloroformate (0.45 mL, 4.15 mmol). The mixture was  
6 stirred overnight and concentrated. Methanol (13 mL) was added and the mixture was  
7 heated to 70 °C for 3 h. The mixture was cooled, concentrated, and purified by silica gel  
8 chromatography (2-10% MeOH/DCM) to afford the N-H morpholine (cleavage of PMB  
9 group). This material was then dissolved in THF (6 mL) after which di-*tert*-butyl  
10 dicarbonate (455 mg, 2.08 mmol) and imidazole (283 mg, 4.15 mmol) were added. After  
11 stirring at room temperature overnight, the mixture was concentrated and directly  
12 purified by column chromatography (5-30% EtOAc/hexane) to give the desired Boc-  
13 morpholine (**73**). For enantioenriched material, the racemic morpholine was subjected to  
14 chiral SFC separation.  
15  
16  
17  
18  
19  
20  
21  
22

23 **3-((7-(5-chloro-3-methyl-2-(((R)-morpholin-2-yl)methyl)phenyl)thieno[3,2-b]pyridin-2-**  
24 **yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione (38)**. The title compound was  
25 synthesized following general procedure I with 2-(bromomethyl)-5-chloro-1-iodo-3-  
26 methylbenzene (**67**) and 4-(4-methoxybenzyl)morpholin-3-one, followed by general  
27 procedure B with 3-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-  
28 2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the  
29 desired product. <sup>1</sup>H NMR (400 MHz, Methanol-d<sub>4</sub>) δ 8.87 (dd, J = 5.8, 2.6 Hz, 1H), 7.81  
30 – 7.63 (m, 2H), 7.49 (d, J = 2.2 Hz, 1H), 7.24 (dd, J = 13.2, 2.3 Hz, 1H), 4.88 (d, J = 6.5  
31 Hz, 2H), 3.89 (dd, J = 13.0, 3.7 Hz, 1H), 3.65 – 3.38 (m, 2H), 3.21 – 3.02 (m, 2H), 2.95  
32 (ddd, J = 17.8, 13.6, 3.6 Hz, 1H), 2.87 – 2.62 (m, 3H), 2.59 (dt, J = 8.1, 3.3 Hz, 2H),  
33 2.48 (s, 3H), 1.63 (tdd, J = 7.9, 4.6, 3.0 Hz, 1H), 1.47 (p, J = 3.6 Hz, 1H). [M+H] 482.0.  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **rac-3-((7-(5-chloro-3-methyl-2-(((2R,3R)-3-methylmorpholin-2-**  
44 **yl)methyl)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione**  
45 (**39**). Step 1: To diisopropylamine (2.3 mL, 16.4 mmol) in THF (50 mL) at 0 °C was  
46 added n-butyllithium (2.5 M in hexane, 6.6 mL, 16.4 mmol) dropwise and the solution  
47 was stirred at 0 °C for 45 min. The mixture was cooled to -78 °C at which time *tert*-butyl  
48 3-oxomorpholine-4-carboxylate (3.0 g, 14.9 mmol) in THF (10 mL) was added dropwise.  
49 After stirring at -78 °C for 1 h, 2-(bromomethyl)-5-chloro-1-iodo-3-methylbenzene (**67**,  
50 10.3 g, 30 mmol) in THF (20 mL) was added dropwise. The mixture was allowed to  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 warm to rt and stirred for 2 h. To this was added sat. aq.  $\text{NH}_4\text{Cl}$  (100 mL), extracted with  
5 EtOAc (2 x 100 mL), dried over  $\text{Na}_2\text{SO}_4$  and concentrated. Silica gel chromatography  
6 afforded tert-butyl 2-(4-chloro-2-iodo-6-methylbenzyl)-3-oxomorpholine-4-carboxylate  
7 (2.64 g, 30%). Step 2: The above compound (800 mg, 1.7 mmol) was dissolved in  
8 diethyl ether (15 mL) and cooled to  $-78\text{ }^\circ\text{C}$ . Then, methylmagnesium bromide (3 M, 1.14  
9 mL, 3.4 mmol) was added dropwise and the solution was stirred for 3 h. The reaction  
10 was quenched with sat. aq.  $\text{NH}_4\text{Cl}$  (20 mL), extracted with EtOAc (2 x 20 mL), and  
11 purified by column chromatography to yield tert-butyl (2-((1-(4-chloro-2-iodo-6-  
12 methylphenyl)-3-oxobutan-2-yl)oxy)ethyl)carbamate (510 mg, ~90% purity). Step 3: The  
13 above material (510 mg) was dissolved in methanol (10 mL) and then conc. HCl (0.72  
14 mL, 8.6 mmol) was added. After stirring for 15 h, the mixture was concentrated, then  
15 dissolved in DCE (10 mL). To this was added sodium triacetoxyborohydride (725 mg,  
16 3.4 mmol) and a drop of acetic acid. After stirring for 15 h, the mixture was concentrated  
17 and purified by column chromatography to yield trans-2-(4-chloro-2-iodo-6-  
18 methylbenzyl)-3-methylmorpholine (200 mg, 32% over 2 steps). Step 4: The above  
19 compound (200 mg, 0.54 mmol) along with di-tert-butyl dicarbonate (143 mg, 0.65  
20 mmol) and 4-dimethylaminopyridine (73 mg, 0.60 mmol) were dissolved in acetonitrile  
21 (5 mL) and stirred for 15 h. After diluting with DCM (50 mL), the solution was washed  
22 with 1N HCl (1 x 30 mL), aq.  $\text{NaHCO}_3$  (1 x 30 mL) and brine (1 x 30 mL), then purified  
23 by column chromatography to yield tert-butyl (2R,3R)-2-(4-chloro-2-iodo-6-  
24 methylbenzyl)-3-methylmorpholine-4-carboxylate (186 mg, 73%). Step 5: The title  
25 compound was synthesized following general procedure B with the above compound  
26 and 3-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)-  
27 3-azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired  
28 product.  $^1\text{H}$  NMR (400 MHz, Methanol- $d_4$ )  $\delta$  8.77 (d,  $J$  = 5.2 Hz, 1H), 7.59 – 7.46 (m,  
29 2H), 7.43 (dd,  $J$  = 4.0, 2.2 Hz, 1H), 7.20 (dd,  $J$  = 12.3, 2.2 Hz, 1H), 4.84 (s, 2H), 4.37 –  
30 4.28 (m, 1H), 4.16 (ddd,  $J$  = 12.0, 6.1, 2.5 Hz, 1H), 3.60 (dd,  $J$  = 13.1, 3.6 Hz, 1H), 3.45  
31 – 3.31 (m, 1H), 3.16 – 3.03 (m, 2H), 2.98 – 2.82 (m, 2H), 2.62 – 2.55 (m, 2H), 2.47 (s,  
32 3H), 1.65 – 1.43 (m, 2H), 0.96 (dd,  $J$  = 12.8, 6.5 Hz, 3H).  $[\text{M}+\text{H}]$  496.0.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

***rac*-3-((7-(5-chloro-3-methyl-2-(((2R,6R)-6-methylmorpholin-2-****yl)methyl)phenyl)thieno[3,2-b]pyridin-2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione**

(40). The title compound was synthesized following general procedure I with 2-(bromomethyl)-5-chloro-1-iodo-3-methylbenzene (67) and 4-(4-methoxybenzyl)-6-methylmorpholin-3-one, followed by general procedure B with 3-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thieno[3,2-b]pyridin-2-yl)methyl)-3-azabicyclo[3.1.0]hexane-2,4-dione, then general procedure D to give the desired product. <sup>1</sup>H NMR (400 MHz, Methanol-d<sub>4</sub>) δ 8.73 (d, *J* = 5.1 Hz, 1H), 7.53 (d, *J* = 1.4 Hz, 1H), 7.51 – 7.38 (m, 2H), 7.20 (d, *J* = 25.8 Hz, 1H), 4.81 (d, *J* = 3.0 Hz, 2H), 3.72 – 3.41 (m, 2H), 3.19 – 2.85 (m, 3H), 2.66 – 2.51 (m, 5H), 2.47 (d, *J* = 2.8 Hz, 3H), 1.61 (td, *J* = 8.1, 4.6 Hz, 1H), 1.43 (p, *J* = 4.8 Hz, 1H), 1.14 – 0.79 (m, 3H). [M+H] 496.0.

**2-(2-bromo-4-chloro-6-methylbenzyl)oxirane (76).** Step 1: 2-bromo-4-chloro-6-methylaniline (60 g, 272 mmol) was added over 30 min to a cooled, stirring solution of tBuONO (48.5 mL, 408 mmol) and allyl bromide (353 mL, 4081 mmol) in acetonitrile (272 mL) with maintaining internal temperature < 5 °C. The mixture was then stirred at room temperature for 20 hours. Upon completion, the mixture was concentrated then partitioned between H<sub>2</sub>O/EtOAc. The layers were separated and the aqueous extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, then concentrated. The crude was purified by silica gel plug (100% hexanes) to yield the allyl arene (49 g, 73%). Step 2: This material (49 g, 201 mmol) was dissolved in DCM (400 mL) then cooled to 0 °C. mCPBA (69.4 g, 301.8 mmol) was added to the stirring mixture in portions over 35 mins with maintaining internal temperature < 5 °C. The mixture was then stirred at room temperature for 20 hours. Upon completion, the mixture was cooled to 0 °C and quenched with sat. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> with internal temperature < 20 °C. The excess m-chlorobenzoic acid was filtered off. The layers were separated and the aqueous was extracted with DCM (2 x 100 mL). The combined organic layers were washed with sat. NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, then concentrated. The crude was purified by column chromatography to yield the title compound (33.1 g, 63%). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 7.43 (d, *J* = 2.2 Hz, 1H),

1  
2  
3  
4 7.12 (d,  $J = 2.2$  Hz, 1H), 3.23 – 3.13 (m, 2H), 3.09 (dd,  $J = 15.4, 6.0$  Hz, 1H), 2.75 (dd,  $J$   
5 = 5.0, 3.7 Hz, 1H), 2.50 (dd,  $J = 4.9, 2.4$  Hz, 1H), 2.38 (s, 3H).  
6

7  
8 **Large-scale synthesis of tert-butyl (R)-2-(2-bromo-4-chloro-6-methylbenzyl)morpholine-**  
9 **4-carboxylate (79).** Step 1: Ethanol amine (30 mL) was added to 2-(2-bromo-4-chloro-6-  
10 methylbenzyl)oxirane (**76**, 13g, 49.7 mmol) in THF (30 mL) at room temperature. The  
11 reaction mixture was stirred at 60 °C for 16 h, then poured into water (1 L) and stirred  
12 for 1 h. The resultant white solid was filtrated and rinsed with water (400 mL) to give the  
13 crude diol (**77**). Solid can be wet for next step. Step 2: In a 1L flask, diol **77** was  
14 suspended in THF (200 mL) and di-*tert*-butyl dicarbonate (16.3 g, 74 mmol) was added  
15 portion wise. This was stirred at room temperature for 1 h. Imidazole (3.4 g, 49.7 mmol)  
16 was added and the solvent was partially removed on the rotavap for 15 min at 40 °C.  
17 The crude mixture was diluted in 50% ethyl acetate/hexanes (400 mL) and rinsed 2  
18 times with 1M HCl (300 mL) and once with brine (100 mL). The organics were dried  
19 over sodium sulfate, filtered, and concentrated to afford a white solid (~19 g, 90%). Step  
20 3: In a 1L flask, this solid (19 g, 44.8 mmol) was suspended in MTBE (250 mL). This  
21 was heated at 50 °C for 20 min to obtain a light cloudy solution. At 0 °C,  
22 triphenylphosphine (14.1 g, 53.8 mmol) was added in one portion. When the  
23 triphenylphosphine was all dissolved, diisopropyl azodicarboxylate (10.6 mL, 53.8  
24 mmol) was added dropwise over 15 min at 0 °C. The reaction was stirred overnight at  
25 room temperature and a solid precipitated over time. The solution was concentrated and  
26 a thick gum was obtained. This was triturated with hexanes (500 mL) to obtain a white  
27 solid. The solid was collected by filtration and dried to obtain a white/light yellow solid  
28 (19g, 105%) – about 80% pure by NMR as the Boc-morpholine. Step 4: The above Boc-  
29 morpholine (~19g, 46 mmol) was dissolved in DCM (200 mL). 4N HCl in dioxane (30  
30 mL) was added and the reaction was stirred at room temperature for 16 h. White solid  
31 slowly formed over time. Diethyl ether (200 mL) was added and the reaction was stirred  
32 for 15 min. The solid was filtered and rinsed with ether (50 mL) to give the racemic  
33 morpholine as the HCl salt (**78**, 9.1 g, 29.3 mmol, 59% from epoxide **76**). Step 5: The  
34 morpholine HCl salt was dissolved in DCM and rinsed with 1M NaOH. The organic  
35 phase was collected, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford the morpholine free  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 base as a colorless gum. Step 6: The morpholine free base was dissolved in DCE (100  
5 mg morpholine per 1 mL DCE). *N*-Ac-D-Leu (unnatural enantiomer, 0.5 equivalents rel.  
6 to free base) was added and the DCE solution stirred and warmed until the solution  
7 became homogeneous. Stirring was stopped and the solution was removed from heat.  
8 Heptane (equal volume to DCE) was then added and the solution was swirled until  
9 homogeneous. The solution was allowed to stand, cooling to room temperature. After  
10 1-2 h, large amounts of crystalline white solid appeared. The mixture was allowed to  
11 stand overnight. The solid was then collected by filtration (this solid is typically 80% ee  
12 in the first batch) and the filtrate (containing mostly the undesired enantiomer) was set  
13 aside. The solid was returned to the original flask and dissolved in hot DCE (85-90 °C,  
14 100 mg morpholine per 1 mL DCE). Once homogeneous, the solution was removed  
15 from the heat and heptane (equal volume to DCE) was then added to the warm mixture  
16 and the solution was swirled until homogeneous. The solution was allowed to stand,  
17 cooling to room temperature. Once most of the solid had emerged from solution, the  
18 solid was collected by filtration (typically 95% ee in the second crystallization) and the  
19 filtrate was added to the previous filtrate and set aside. The recrystallization procedure  
20 was repeated a third time to afford solid of >99% ee. Step 7: To the above  
21 enantioenriched morpholine (5.55g, 11.62 mmol) in DCM (50 mL) was added  
22 triethylamine (4.84mL, 34.85 mmol) and di-tert-butyl dicarbonate (3.8g, 17.42 mmol).  
23 This was stirred at room temperature for 1 hour, then imidazole (1.19 g, 17.4 mmol) was  
24 added. After stirring for an additional 30 min, the mixture was diluted with 1M aq. HCl  
25 and stirred vigorously for 1 min. The organic layer was washed with water, then 1M  
26 NaOH, then the aqueous layer was back extracted 2x with DCM. The combined  
27 organics were dried, filtered, and concentrated to give the final product, enantioenriched  
28 morpholine **79** (31% over 3 steps). <sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 7.42 (d, *J* = 2.2  
29 Hz, 1H), 7.10 (d, *J* = 2.4 Hz, 1H), 3.94 (bs, 1H), 3.80 (dd, *J* = 11.7, 3.4 Hz, 2H), 3.62  
30 (bs, 1H), 3.40 (td, *J* = 11.8, 2.8 Hz, 1H), 2.98 – 2.83 (m, 3H), 2.72 (bs, 1H), 2.38 (s, 3H),  
31 1.45 (s, 9H). [M+Na] 426.0.

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 **3-((7-(5-chloro-3-methyl-2-(((R)-morpholin-2-yl)methyl)phenyl)thieno[3,2-b]pyridin-2-**  
54 **yl)methyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione (41)**. The title compound  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 was synthesized following general procedure B with enantioenriched morpholine **79** and  
5 2-(((tert-butyldimethylsilyl)oxy)methyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
6 yl)thieno[3,2-b]pyridine (**48**), followed by general procedure G with 6,6-dimethyl-3-  
7 azabicyclo[3.1.0]hexane-2,4-dione, then general procedure C to give the desired  
8 product. <sup>1</sup>H NMR (400 MHz, Methanol-*d*<sub>4</sub>) δ 8.88 (t, J = 4.8, 3.8 Hz, 1H), 7.81 – 7.65  
9 (m, 2H), 7.49 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 11.2, 2.3 Hz, 1H), 4.93 (d, J = 5.0 Hz,  
10 2H), 3.89 (dd, J = 13.0, 3.7 Hz, 1H), 3.67 – 3.39 (m, 2H), 3.20 – 3.02 (m, 2H), 3.02 –  
11 2.89 (m, 1H), 2.88 – 2.54 (m, 3H), 2.52 (d, J = 3.6 Hz, 2H), 2.48 (s, 3H), 1.25 (d, J = 2.0  
12 Hz, 3H), 1.13 (d, J = 8.5 Hz, 3H). [M+H] 510.0.  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 **X-ray Co-crystallography.** Amino acids 208-560 of human USP7 were expressed in  
23 E.coli and purified using a GST-Tag. The GST-Tag was cleaved off via PreScission  
24 protease after affinity purification and the GST-tag was removed by an additional affinity  
25 purification step on GSTrap. Finally, a size exclusion chromatography step was  
26 performed using a S-200 26/60 column in 20mM Tris 8.0, 100mM NaCl, 10% Glycerol,  
27 5mM DTT buffer and the sample was concentrated to 27 mg/ml. Crystallization was  
28 performed at 4 °C by vapor diffusion method at a protein concentration of 17 mg/ml and  
29 a ligand concentration of 10 mM (10% DMSO). Incubation time for the soak was 2 days.  
30 The crystallization reservoir condition contained 22.00 %w/v PEG 3350 and 0.50  
31 M NH<sub>4</sub> Acetate. Crystals were cryo-protected by 25% Glycerol in reservoir solution.  
32 Diffraction data were collected at the Swiss Light Source (SLS).  
33  
34  
35  
36  
37  
38  
39  
40

41 **Computational Details.** The co-crystal structure of compound **7** in complex with USP7  
42 was prepared for modeling at pH 7.3 using the Protein Preparation Wizard in Maestro  
43 11.2 (Schrödinger, LLC, New York, NY, 2017). This method first adds hydrogens,  
44 assigns bond orders to the ligand and then optimizes the hydrogen-bonding network of  
45 the receptor. An all-atom minimization is then performed, with a 0.3Å heavy-atom  
46 RMSD cutoff applied using the OPLS3 forcefield.<sup>29</sup> WaterMap, described in detail  
47 elsewhere,<sup>30,31</sup> uses a molecular dynamics approach to predict the thermodynamic  
48 properties of water molecules in a protein environment. This includes each water site's  
49 entropy, enthalpy, and free energy. WaterMap calculations were run with default  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 settings (2ns simulation time with waters analyzed with 10 Å of the ligand), using the  
5 prepared co-crystal structure of compound **7** in complex with USP7 (PDB code 6VN5),  
6 both with and without the ligand present. FEP+ calculations were carried out using the  
7 2017-2 release of the Schrödinger Suite with the OPLS3 forcefield. Default lambda  
8 schedules and REST<sup>32</sup> regions were used in FEP+ while simulation time ranged from  
9 10ns to 15ns, to allow for convergence. Ligands were prepared using LigPrep<sup>33</sup> and  
10 docked using Glide<sup>34</sup> with default settings. In cases where ligand alignment was  
11 insufficient, flexible ligand alignment in Maestro was used starting from the native ligand  
12 conformation as reference.  
13  
14  
15  
16  
17  
18

19  
20 **USP7 Biochemical Assay:** A 25 µl reaction volume containing recombinant full-length  
21 USP7 (62 pM) in 20 mM HEPES pH 7.3, 150 mM NaCl, 1 mM TCEP, and 125 µg/ml  
22 BSA was assembled in wells of 384 well plates. Compounds were dispensed with a  
23 Hewlett Packard D300 digital dispenser (1% final DMSO). Following a 30-minute  
24 incubation at room temperature, ubiquitin-rhodamine (BostonBiochem) was added with  
25 the D300 to a final concentration of 100 nM and the reaction was allowed to proceed for  
26 1 hour at room temperature protected from light. The reaction was stopped by the  
27 addition of 5 µl 1M acetic acid. Rhodamine fluorescence was measured using an  
28 Envision plate reader (Perkin Elmer) and IC<sub>50</sub> values were determined by non-linear  
29 regression using a 4-parameter fit in the Dotmatics software package. Values presented  
30 are the average of n = 2 or more determinations, where the value of each determination  
31 is within a 3-fold difference of each other.  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 **DUB Selectivity Profiling:** Deubiquitinase selectivity profiling was conducted by  
42 Ubiquigent (Dundee, UK) using a similar assay protocol with the following changes:  
43 assay buffer was 40 mM Tris/HCl pH 7.4, 5% glycerol, 0.005% Tween-20, 1 mM DTT,  
44 0.05 mg/ml ovalbumin, and the reaction was stopped by the addition of 5 µl 100 mM N-  
45 Ethylmaleimide.  
46  
47  
48  
49

50 **p53-Luciferase Reporter Gene Assay:** RKO cells stably transfected with a p53  
51 luciferase reporter vector (Signosis) were seeded at 2500 cells per well in 25µl of  
52 recommended media in 384-well black-walled tissue plates (Greiner). Compounds were  
53 added with a D300 digital dispenser (0.5% final DMSO). Following an 18-hour  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 incubation, p53-dependent luciferase levels were measured via Bright-Glo Luciferase  
5 (Promega), following the manufacturer's instructions, using a CLARIOstar plate reader  
6 (BMG LABTECH). IC<sub>50</sub> values were determined by non-linear regression using a 4-  
7  
8 parameter fit in the Dotmatics software package.  
9

10  
11 **Cell Culture, Cell Treatments, and Viability Assays (MM.1S, H526, RKO).** All cell lines  
12 were purchased from American Type Culture Collection. For all cell lines, identity was  
13 confirmed by short tandem repeat profiling and culturing was performed in  
14 recommended growth medium. For studies evaluating cellular effects of compound  
15 treatment, 250 to 2,000 cells in 40 µl of recommended medium were seeded per well in  
16 384-well plates (Corning 3764). DMSO-solubilized compounds were added in duplicate  
17 in a two-fold dilution series using a D300e Digital Dispenser (Hewlett-Packard).  
18 Following a 5-day incubation, cell viability was measured using CellTiter-Glo (Promega)  
19 following the manufacturer's instructions. Luminescence was measured using a  
20 CLARIOstar plate reader (BMG LABTECH) and normalized to that of DMSO-treated  
21 cells. IC<sub>50</sub> values were determined by non-linear regression using a 4-parameter fit in  
22 Prism (GraphPad Software).  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **Animal experiments:** MM.1S and H526 xenograft studies were conducted at Crown Bio  
33 (Beijing, China) and RAPT Therapeutics, respectively, according to the guidelines  
34 approved by the respective Institutional Animal Care and Use Committees (IACUC).  
35 MM.1S cells were inoculated in PBS into irradiated NOD/SCID mice, while H526 cells  
36 were inoculated in PBS/Matrigel (Corning) into Nu/Nu mice (Jackson Laboratories). At  
37 the start of the study, NOD/SCID mice were 9-10 weeks old and 17.2-22.3 g in weight,  
38 while Nu/Nu mice were 7 weeks old and 18.1-25.4 g in weight. Mice were randomized  
39 into groups when mean tumor size reached 150 mm<sup>3</sup> (MM.1S) or 50-100 mm<sup>3</sup> (H526),  
40 respectively, with 10 mice per group. Drug administration by oral gavage was started on  
41 day of randomization. Tumor volumes and body weights were subsequently measured  
42 twice per week. Tumor volumes were calculated using the formula:  $V = 0.5(A \times B^2)$ ,  
43 where A and B are the long and short diameters of the tumor, respectively. If the  
44 animal's body weight dropped to less than 90% of the original weight, a dosing holiday  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 was given until their body weight surpassed the 90% mark. All animals were included in  
4 the tumor growth plots, regardless of whether they received a dosing holiday.  
5  
6  
7  
8  
9

## 10 11 12 **ANCILLARY INFORMATION** 13

### 14 15 16 **Supporting Information.** 17

18  
19 The following files are available free of charge: molecular formula strings; biochemical  
20 and cellular potency correlation; target engagement for compound **30**; DUB selectivity  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 profile for compound **30**; view of USP7 showing solvent-exposed Tyr-465; PK curves for  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196

1  
2  
3 †These authors contributed equally to the preparation of this manuscript. All authors  
4  
5  
6  
7 have given approval to the final version of the manuscript.  
8  
9

## 10 **Notes**

11  
12  
13  
14 The authors declare the following competing financial interests: The majority of authors  
15  
16  
17 of this manuscript are or were employees of RAPT Therapeutics, Inc. (formerly known  
18  
19  
20 as FLX Bio, Inc.).  
21  
22  
23

## 24 **Acknowledgments**

25  
26  
27  
28 We would like to thank Alan Hao and Joseph Fan from AIM Biosciences for helping to  
29  
30  
31 produce large quantities of some important synthetic intermediates. Stephan Krapp and  
32  
33  
34 Michael Blaesse from Proteros Biostructures GmbH are acknowledged for helping solve  
35  
36  
37 the X-ray crystal structures presented in this manuscript. Finally, we would like to thank  
38  
39  
40 all current and former RAPT Therapeutics employees for all their hard work, dedication,  
41  
42  
43 and helpful discussions related to our USP7 program.  
44  
45  
46  
47

## 48 **Abbreviations**

49  
50  
51  
52 USP7, ubiquitin-specific protease 7; DUB, deubiquitinase; MDM2, mouse double minute  
53  
54  
55 2 homolog; p53, tumor protein p53; FOXP3, forkhead box P3; USP1, ubiquitin-specific  
56  
57  
58  
59  
60

1  
2  
3 protease 1; UCH-L3, ubiquitin carboxy-terminal hydrolase isozyme L3; USP47,  
4  
5  
6  
7 ubiquitin-specific protease 47; LipE, lipophilic efficiency; IV, intravenous; PO, per os  
8  
9  
10 (administered orally); AUC, area under the curve; SAR, structure-activity relationship;  
11  
12  
13 PK, pharmacokinetics; hERG, human ether-a-go-go-related gene potassium ion  
14  
15  
16  
17 channel; CYP, cytochrome P450; FEP+, free energy perturbation; NOD-SCID, non-  
18  
19  
20 obese diabetic-severe combined immunodeficient, DMF, dimethylformamide, *m*-CPBA,  
21  
22  
23 meta-chloroperoxybenzoic acid; TEMPO, 2,2,6,6-Tetramethylpiperidin-1-yl)oxyl; T3P,  
24  
25  
26  
27 propylphosphonic acid anhydride; TBS, tert-butyldimethylsilyl; PMB, para-  
28  
29  
30  
31 methoxybenzyl; TLC, thin layer chromatography.  
32  
33  
34  
35  
36  
37

## 38 REFERENCES

- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 
- <sup>1</sup> Bhattacharya, S.; Chakraborty, D.; Basu, M.; Ghosh, M. K. "Emerging Insights into HAUSP (USP7) in Physiology, Cancer, and Other Diseases." *Signal Transduct. Target Ther.* **2018**, *3*, 17.
- <sup>2</sup> Tavana, O.; Gu, W. "Modulation of the p53/MDM2 Interplay by HAUSP Inhibitors." *J. Mol. Cell Biol.* **2017**, *9*, 45-52.

1  
2  
3  
4  
5  
6 <sup>3</sup> van Loosdregt, J.; Fleskens, V.; Fu, J.; Brenkman, A. B.; Bekker, C. P. J.; Pals, C. E.  
7 M. G.; Meering, J.; Berkers, C. R.; Barbi, J.; Gröne, A.; Sijts, A. J. A. M.; Maurice, M.  
8 M.; Kalkhoven, E.; Prakken, B. J.; Ovaa, H.; Pan, F.; Zaiss, D. M. W.; Coffey, P. J.  
9  
10  
11 “Stabilization of the Transcription Factor Foxp3 by the Deubiquitinase USP7 Increases  
12 Treg-Cell-Suppressive Capacity.” *Immunity*, **2013**, *39*, 259-271.

13  
14  
15 <sup>4</sup> Agathangelou, A.; Smith, E.; Davies, N. J.; Kwok, M.; Zlatanou, A.; Oldreive, C. E.;  
16 Mao, J.; Costa, D. D.; Yadollahi, S.; Perry, T.; Keams, P.; Skowronska, A.; Yates, E.;  
17 Parry, H.; Hillmen, P.; Reverdy, C.; Delansorne, R.; Paneesha, S.; Pratt, G.; Moss, P.;  
18 Taylor, A. M. R., Stewart, G. S.; Stankovic, T. “USP7 Inhibition Alters Homologous  
19 Recombination Repair and Targets CLL Cells Independently of ATM/p53 Functional  
20 Status.” *Blood*, **2017**, *130*, 156-166.

21  
22  
23 <sup>5</sup> Li, P.; Liu, H.-M. “Recent Advances in the Development of Ubiquitin-Specific-  
24 Processing Protease 7 (USP7) Inhibitors.” *Eur. J. Med. Chem.* **2020**, *191*, 112107.

25  
26  
27 <sup>6</sup> Colland, F.; Gourdel, M.-E. “Selective and Reversible Inhibitors of Ubiquitin Specific  
28 Protease 7.” WO2013030218, **2013**.

29  
30  
31 <sup>7</sup> Turnbull, A. P.; Ioannidis, S.; Krajewski, W. W.; Pinto-Fernandez, A.; Heride, C.;  
32 Martin, A. C. L.; Tonkin, L. M.; Townsend, E. C.; Buker, S. M.; Lancia Jr, D. R.;  
33 Caravella, J. A.; Toms, A. V.; Charlton, T. M.; Lahdenranta, J.; Wilker, E.; Follows, B.  
34 C.; Evans, N. J.; Stead, L.; Alli, C.; Zarayskiy, V. V.; Talbot, A. C.; Buckmelter, A. J.;  
35 Wang, M.; McKinnon, C. L.; Saab, F.; McGouran, J. F.; Century, H.; Gersch, M.;  
36 Pittman, M. S.; Marshall, C. G.; Raynham, T. M.; Simcox, M.; Stewart, L. M. D.;  
37 McLoughlin, S. B.; Escobedo, J. A.; Bair, K. W.; Dinsmore, C. J.; Hammonds, T. R.;  
38 Kim, S.; Urbé, S.; Clague, M. J.; Kessler, B. M.; Komander, D. “Molecular Basis of  
39 USP7 Inhibition by Selective Small-Molecule Inhibitors.” *Nature*, **2017**, *550*, 481-486.

40  
41  
42 <sup>8</sup> Gavory, G.; O’Dowd, C. R.; Helm, M. W.; Flasz, J.; Arkoudis, E.; Dossang, A.; Hughes,  
43 C.; Cassidy, E.; McClelland, K.; Odrzywol, E.; Page, N.; Barker, O.; Miel, H.; Harrison,  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 T. "Discovery and Characterization of Highly Potent and Selective Allosteric USP7  
7 Inhibitors." *Nat. Chem. Biol.* **2018**, *14*, 118-125.

8  
9  
10 <sup>9</sup> Kotschy, A.; Wéber, C.; Vasas, A.; Molnár, B.; Kiss, Á.; Macias, A.; Murray, J. B.;  
11 Lewkowicz, E.; Geneste, O.; Chanrion, M.; Demarles, D. "New (Hetero)aryl-Substituted-  
12 Piperidinyl Derivatives, A Process for Their Preparation and Pharmaceutical  
13 Compositions Containing Them." EP2017064062, **2017**.

14  
15  
16  
17  
18 <sup>10</sup> Lamberto, I.; Liu, X.; Seo, H. S.; Schauer, N. J.; Iacob, R. E.; Hu, W.; Das, D.;  
19 Mikhailova, T.; Weisberg, E. L.; Engen, J. R.; Anderson, K. C.; Chauhan, D.; Dhe-  
20 Paganon, S.; Buhrlage, S. J. "Structure-Guided Development of a Potent and Selective  
21 Non-Covalent Active-Site Inhibitor of USP7." *Cell Chem. Biol.* **2017**, *24*, 1490-1500.

22  
23  
24  
25  
26 <sup>11</sup> Kategaya L., Di Lello P., Rougé L., Pastor R., Clark K. R., Drummond J., Kleinheinz  
27 T., Lin E., Upton J. P., Prakash S., Heideker J., McClelland M., Ritorto M. S., Alessi D.  
28 R., Trost M., Bainbridge T. W., Kwok M. C. M., Ma T. P., Stiffler Z., Brasher B., Tang Y.,  
29 Jaishankar P., Hearn B. R., Renslo A. R., Arkin M. R., Cohen F., Yu K., Peale F., Gnad  
30 F., Chang M. T., Klijn C., Blackwood E., Martin S. E., Forrest W. F., Ernst J. A.,  
31 Ndubaku C., Wang X., Beresini M. H., Tsui V., Schwerdtfeger C., Blake R. A., Murray  
32 J., Maurer T., Wertz I. E. "USP7 Small-Molecule Inhibitors Interfere with Ubiquitin  
33 Binding." *Nature*, **2017**, *550*, 534-538.

34  
35  
36  
37  
38  
39  
40 <sup>12</sup> Di Lello P., Pastor R., Murray J. M., Blake R. A., Cohen F., Crawford T. D., Drobnick  
41 J., Drummond J., Kategaya L., Kleinheinz T., Maurer T., Rougé L., Zhao X., Wertz I.,  
42 Ndubaku C., Tsui V. "Discovery of Small-Molecule Inhibitors of Ubiquitin Specific  
43 Protease 7 (USP7) Using Integrated NMR and in Silico Techniques." *J. Med. Chem.*  
44 **2017**, *60*, 10056-10070.

45  
46  
47  
48  
49  
50 <sup>13</sup> Wu, J.; Kumar, S.; Wang, F.; Wang, H.; Chen, L.; Arsenault, P.; Mattern, M.;  
51 Weinstock, J. "Chemical Approaches to Intervening in Ubiquitin Specific Protease 7  
52 (USP7) Function for Oncology and Immune Oncology Therapies." *J. Med. Chem.* **2018**,  
53 *61*, 422-443.

1  
2  
3  
4  
5  
6 <sup>14</sup> Pozhidaeva, A.; Valles, G.; Wang, F.; Wu, J.; Sterner, D. E.; Nguyen, P.; Weinstock,  
7 J.; Kumar, K. G. S.; Kanyo, J.; Wright, D.; Bezsonova, I. "USP7-Specific Inhibitors  
8 Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms." *Cell*  
9 *Chem. Biol.* **2017**, *24*, 1501-1512.

10  
11  
12  
13  
14 <sup>15</sup> Ohol, Y. M.; Sun, M. T.; Cutler, G.; Leger, P.; Hu, D.; Biannic, B.; Rana, P.; Cho, C.;  
15 Jacobson, S.; Wong, S.; Sanchez, J.; Shah, N.; Young, K.; Han, X.; Bradford, D.;  
16 Kozon, N.; Abraham, B.; Pookot, D.; Okano, A.; Maung, J.; Suthram, S.; Adusumilli, L.;  
17 Kaveri, D.; Talay, O.; Marshall, L.; Colas, C.; Kim, A.; Schwarz, J.; Wustrow, D.;  
18 Brockstedt, D.; Kassner, P. "Novel, Selective Inhibitors of USP7 Uncover Multiple  
19 Mechanisms of Antitumor Activity in Vitro and in Vivo." *Manuscript in submission.* **2020**.

20  
21  
22  
23  
24  
25 <sup>16</sup> Schrödinger Release 2016-2: WaterMap, Schrödinger, LLC, New York, NY, 2016.

26  
27  
28 <sup>17</sup> Data not shown. See reference 15.

29  
30  
31  
32  
33 <sup>18</sup> A strong correlation between USP7 biochemical potency and cellular p53 response  
34 suggests that this response is due to USP7 inhibitor-mediated MDM2 destabilization.  
35 See Supporting Figure 1.

36  
37  
38  
39  
40 <sup>19</sup> Takahashi, T.; D'Amico, D.; Chiba, I.; Buchhagen, D. L.; Minna, J. D. "Identification of  
41 Intronic Point Mutations as an Alternative Mechanism for p53 Inactivation in Lung  
42 Cancer." *J. Clin. Invest.* **1990**, *86*, 363-369.

43  
44  
45 <sup>20</sup> See Supporting Figure 2 and reference 15 for target engagement assay.

46  
47  
48 <sup>21</sup> See Supporting Figure 3 for a complete list of DUBs tested in the selectivity panel.

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 <sup>22</sup> Wang, L.; Wu, Y.; Deng, Y.; Kim, B.; Pierce, L.; Krilov, G.; Lupyan, D.; Robinson, S.;  
Dahlgren, M. K.; Greenwood, J.; Romero, D. L.; Masse, C.; Knight, J. L.; Steinbrecher,  
T.; Beuming, T.; Damm, W.; Harder, E.; Sherman, W.; Brewer, M.; Wester, R.; Murcko,  
M.; Frye, L.; Farid, R.; Lin, T.; Mobley, D. L.; Jorgensen, W. L.; Berne, B. J.; Friesner, R.  
A.; Abel, R. "Accurate and Reliable Prediction of Relative Ligand Binding Potency in

1  
2  
3  
4  
5  
6 Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and  
7 Force Field." *J. Am. Chem. Soc.* **2015**, *137*, 2695–2703.

8  
9  
10 <sup>23</sup> See Supporting Figure 4 for a visualization of solvent-exposed Tyr-465.

11  
12 <sup>24</sup> See Supporting Figure 5 for PK curves of compound **41** in different mouse species.

13  
14  
15 <sup>25</sup> Compound **41** is measured to be 95.3% bound to mouse plasma proteins as  
16 measured by ultracentrifugation.

17  
18  
19 <sup>26</sup> Luzzio, M. J.; Yang, B. V.; Marx, M. A. "Thiophene Derivatives Useful as Anticancer  
20 Agents." US 20020004511, **2002**.

21  
22  
23 <sup>27</sup> Amezcuita-Valencia, M.; Alper, H. "PdI<sub>2</sub>-Catalyzed Regioselective Cyclocarbonylation  
24 of 2-Allyl Phenols to Dihydrocoumarins." *Org. Lett.* **2014**, *16*, 5827-5829.

25  
26  
27 <sup>28</sup> Ek, F.; Axelsson, O.; Wistrand, L.-G.; Frejd, T. "Aromatic Allylation via Diazotization:  
28 Metal-Free C–C Bond Formation." *J. Org. Chem.* **2002**, *67*, 6376-6381.

29  
30  
31 <sup>29</sup> Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan,  
32 D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W.  
33 L.; Abel, R.; Friesner, R. A. "OPLS3: A Force Field Providing Broad Coverage of Drug-  
34 like Small Molecules and Proteins." *J. Chem. Theory Comput.* **2016**, *12*, 281-296.

35  
36  
37 <sup>30</sup> Young, T.; Abel, R.; Kim, B.; Berne, B. J.; Friesner, R. A., "Motifs for Molecular  
38 Recognition Exploiting Hydrophobic Enclosure in Protein-Ligand Binding." *Proc. Nat.*  
39 *Acad. Sci.* **2007**, *104*, 808-813.

40  
41  
42 <sup>31</sup> Abel, R.; Young, T.; Farid, R.; Berne, B.J.; Friesner, R.A., "Role of the Active-Site  
43 Solvent in the Thermodynamics of Factor Xa Ligand Binding," *J. Am. Chem.*  
44 *Soc.*, **2008**, *130*, 2817-2831.

45  
46  
47 <sup>32</sup> Wang, L.; Friesner, R. A.; Berne, B. J. "Replica Exchange with Solute Scaling: a More  
48 Efficient Version of Replica Exchange with Solute Tempering (REST2)." *J. Phys. Chem.*  
49 *B*, **2011**, *115*, 9431-9438.

1  
2  
3  
4  
5  
6 <sup>33</sup> Schrödinger Release 2017-2: LigPrep, Schrödinger, LLC, New York, NY, 2017.  
7

8 <sup>34</sup> Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.;  
9 Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin,  
10 P. S. "Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and  
11 Assessment of Docking Accuracy." *J. Med. Chem.* **2004**, *47*, 1739-1749.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Table of Contents graphic:  
4  
5  
6  
7

